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Abstract  III 
Abstract 
Cancer diseases causes 7.6 million deaths worldwide per year, and the number 
of affected persons and deaths are increasing steadily. 
Treatment of cancer consists of three mainstays: surgery, radiotherapy and 
chemotherapy. At the moment, platinum(II) complexes are the only metal-based 
drugs in cancer chemotherapy, but also other complexes with a different metal 
center have a high potential as antitumor agents, such as ruthenium that has 
the ability to mimic iron, as well as osmium or copper that plays an important 
role in biological systems. The combination of metals with biologically active 
ligands can improve the cytotoxic profile, e.g. by an increase of drug uptake or a 
decrease of side effects.  
In this work, a range of complexes of copper, ruthenium and osmium with 
indoloquinolines as biologically active ligands were tested for their cytotoxicity. 
Indoloquinolines have a planar structure and are known for their high potential 
to intercalate into DNA. Therefore cell cycle and DNA intercalation studies were 
performed to obtain information about the behavior of the compounds in 
biological environment. The aim of this work was to find structure-activity 
relationships and to gain insight into the mode of action of the examined 
compounds. 
Cytotoxicity was determined by the colorimetric MTT assay in three different cell 
lines: A549 (non-small cell lung cancer), CH1 (ovarian carcinoma) and SW480 
(colon carcinoma). The chosen cell lines have different sensitivities against 
chemotherapeutics in clinical use. A549 is a multidrug-resistant cell line, 
whereas CH1 is sensitive to a broad variety of drugs. Comparison with the new 
complexes enables conclusions about resistance mechanisms. 
All tested copper compounds show strong cytotoxic effects in all three cell lines, 
with some IC50 values down to the nM range, whereas ruthenium and osmium 
compounds were less active. 
 
IV  Abstract 
Cell cycle studies were performed to determine the influence of some copper 
based compounds of the cell cycle, such as arrest in a defined phase. Due to 
the planar indoloquinoline moiety, DNA intercalation was studied as a potential 
mode of action. However, no effects on the cell cycle and no intercalating 
properties in the methyl green assay were found.  
Western blotting was used verify to apoptosis induction by the new copper 
complexes, by using cleavage of the caspase substrate PARP as an indicator 
for apoptosis. Indeed, increasing concentrations of the studied compounds 
resulted in increasing cleavage of PARP.  
 
 
Zusammenfassung  V 
Zusammenfassung 
Krebs ist eine Erkrankung, deren Anzahl an betroffenen Personen und Todes-
fällen stetig steig. Mittlerweile sterben weltweit bereits 7,6 Millionen Menschen 
pro Jahr. 
Die Krebstherapie besteht aus drei Hauptsäulen, chirugisch Therapie, 
Radiotherapie und Chemotherapie. Metall-Komplexe gehören zu einer der 
unterschiedlichen Substanzklassen in der Chemotherapie. Zytostatika auf 
Platinbasis sind bereits in Verwendung, aber auch andere Komplexe mit 
unterschiedlichen Metallzentren zeigen ein hohes Potential, als tumor-
hemmende Substanzen eingesetzt zu werden. Als interessante Kandidaten 
bieten sich zum Beispiel Ruthenium, welches Eisen imitieren kann, sowie 
Osmium oder Kupfer, das eine große Rolle in biologischen Systemen spielt, an. 
Die Kombination von Metallen mit biologisch aktiven Liganden kann dieses 
Potential noch steigern. 
In dieser Arbeit wurden Kupfer-Komplexe mit Indoloquinolin Liganden 
untersucht. Auch einige Ruthenium- und Osmium-Komplexe mit Indoloquinolin 
Liganden wurden auf ihre Zytotoxizität getestet. Indoloquinoline sind biologisch 
aktive Liganden und haben wegen ihrer planaren Struktur die Möglichkeit in die 
DNA zu interkalieren. Das Ziel dieser Arbeit war es, Struktur-Wirkungs-
Beziehungen sowie andere zelluläre Effekte festzustellen. 
Die Zytotxizität wurde mittels MTT-Assay ermittelt. Die drei verwendeten 
Zelllinien, A549 (nicht-kleinzelliges Bronchialkarzinom), CH1 (Ovarialkarzinom) 
und SW480 (Kolonkarzinom), zeigen unterschiedliche Sensitivitäten gegen 
verschiedene Zytostatika. A549 ist eine multidrug-resistente Zelllinie, 
wohingegen CH1 auf ein breites Spektrum an Substanzen anspricht.  
Alle getesteten Kuperkomplexe zeigten eine sehr hohe Zytotoxizitt in allen drei 
Zelllinien. Es wurden einige IC50-Werte im nanomolaren Bereich gefunden. Die 
Ruthenium- und Osmium-Verbindungen hingegen waren weniger aktiv als 
erwartet. 
VI  Zusammenfassung 
Zellzyklus-Untersuchungen mittels Durchflusszytometrie wurden durchgeführt, 
um den Einfluss der Kupfer-Komplexe auf den Zellzyklus zu untersuchen. 
Weiters wurden auf Grund der planaren Struktur der Indoloquinoline DNA-
interkalierende Eigenschaften mittels Methylgrün-Assay untersucht, um fest-
zustellen, ob dies einen möglichen Wirkmechanismus darstellt. Es konnten 
jedoch keine Effekte auf den Zellzyklus und keine Interkalationseigenschaften 
im Methylgrün-Assay gefunden werden.  
Western Blotting wurde als Methode herangezogen, um Apoptoseinduktion 
durch die neuen Kupfer-Komplexe nachzuweisen. Die Spaltung des Caspase-
Substrats PARP wurde als Apoptoseindikator herangezogen. Mit zunehmender 
Konzentration der zu testenden Substanzen konnte ein Anstieg an gespaltenem 
PARP festgestellt werden. 
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Abbreviations 1 
1 Abbreviations 
BSA Bovine Serum Albumin 
Cdk Cycline dependent kinase 
DMSO Dimethylsulfoxid 
DNA Desoxiribo Nucleic Acid 
dsDNA double stand DNA 
EtBr Ethidium Bromide 
HAS Human serum albumin 
HRP HorseRadishPeroxidase 
KP1019 Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] 
KP1779 [(?6-p-Cymene)OsII(L2)Cl]Cl, (?6-p-cymene)(?N’-[11H- indolo[3,2-
c]quinolin-6-ylidene]-?N,N-dimethylethane- 1,2-
diamine)chloridoosmium(II) chloride 
MTT 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
NAMI-A imidazolium trans-[tetrachloro(dimethylsulfoxi- de)(1H-
imidazole)ruthenate(III)] 
PBS Phosphate Buffered Saline 
PI Propidium Iodide 
SDS Sodium Dodecyl Sulfat 
TBST Tris-Buffered Saline + Tween 20 
TRIS 2-Amino-2-hydroxymethyl-propane-1,3-diol 
 
 
2 Introduction 
2 Introduction 
2.1 Aspects of cancer 
2.1.1 History 
Cancer is not a modern disease. The word cancer is the Latin translation 
(Celsus 28-50 BC) of the Greek word for crab (Hippocrates 460-370 BC), which 
was used due to the form of a breast tumor reminding of a crab. Earliest 
descriptions of cancer, although it was not called cancer back then, were 
discovered in Egypt about 3000 BC. Other evidences of cancer were found in 
human mummies and fossilized bones, too. At that time there was no treatment 
for this disease, though. 
In the 18th century when scientists started to use autopsies regularly, John 
Hunter, a Scottish surgeon, suggested that if a tumor has not invaded the 
surrounding tissue it should be removed. After the development of anesthesia, 
cancer operations started to improve. [1] 
 
2.1.2 Epidemiology 
Nowadays cancer is one leading cause of death in the world. 7.6 million deaths 
due to cancer were counted in 2008 (approximately 13% of all deaths), and 
70% of them can be found in low- and middle-income countries. The World 
Health Organization (WHO) predicts that a decrease of cancer incidences is not 
likely. Quite on the opposite, in the year 2030 it will be responsible for more 
than 11 million deaths. The most frequent forms of cancer include lung cancer, 
stomach cancer, liver cancer, colorectal cancer, prostate and breast cancer.  
Different risk factors can be linked to increased occurrence of cancer such as 
consumption of alcohol, use of tobacco and chronic infections with different 
viruses such as hepatitis B and C, but also genetic factors and external agents 
such as ultraviolet and other ionizing radiation or chemical agents. 
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With different strategies avoiding risk factors more than 30% of deaths caused 
by cancer could be prevented, according to an estimation of the WHO. [2] 
Fig. 1 Incidence and mortality of the most frequent cancers in men and women worldwide. [3] 
 
As shown in Fig. 1, different types of cancer affect men and women with 
different probabilities. Men have a higher risk to die of lung, liver or stomach 
cancer, whereas women have a higher risk to die of breast, lung or colorectal 
cancer. 
 
2.1.3 Cancerogenesis 
Cancerogenesis is defined as the development of cancer. The two main 
characteristics of cancer are, firstly, to escape the growth and proliferation 
controls and, secondly, to invade surrounding tissues. As long as the tumor is 
not invasive, it is called benign. When it starts to invade other tissues, it is called 
a malignant tumor. A malignant tumor, spreads through the blood or lymphatic 
vessels throughout the body and forms secondary tumors (metastases). 
Mutations or epigenetic changes can lead to cancer. It should be kept in mind, 
though, that cancer cannot arise from a single mutation. In fact a larger number 
of mutations that provide the cell with a growth advantage as compared to the 
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neighboring cells can lead to cancer. Normally, the cell has checkpoint controls, 
which will lead to a cell cycle arrest if, for example, DNA has been damaged. 
This allows the body to initiate repair mechanisms. If it is not possible to restore 
the DNA in the original form, the cell will undergo apoptosis. Often the response 
to DNA damage is inactivated; in particular, mutations in the p53 pathway, a 
tumor suppressor gene, are frequently found that can result in the inactivation of 
apoptosis. These are just two examples of how cancer cells survive, but there 
are many possibilities more that are already known. [4] 
 
2.1.4 Treatment 
In cancer treatment three mainstays of therapy exist: 
• Surgery 
• Radiotherapy 
• Chemotherapy 
Apart from that other methods such as immunotherapy and hormone therapy 
can also be employed. 
Surgical Therapy: Surgery is the oldest method to fight cancer. Already in the 
19th century J. Abernethy described such a method for cancer treatment. At that 
time, the main problem was that anesthesia and antisepsis were not yet 
developed. Nowadays solid malignant tumors are removed completely with 
some of their surrounding tissue as far as possible. Surgery is also used for 
palliation of advanced cancer that e.g. has already metastasized and cannot be 
cured by surgery. 
Radiotherapy: Radiotherapy evolved shortly after the discovery of X-ray by 
Roentgen in 1895. This technology developed rapidly and as early as in the 
1920s an effective therapy against laryngeal cancer was introduced. Ionizing 
radiation inhibits cell proliferation and can damage DNA for example. Normally, 
healthy cells have a repair system that will work against such damages. In 
tumor cells this system works less efficiently and the cell will die. It is important 
to carefully choose the appropriate radiation dose, time and number of 
treatments to kill the tumor cells with as little a risk as possible for subsequent 
complications. 
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Chemotherapy: The era of chemotherapy emerged in the 1940s with the 
development of nitrogen mustard. Nowadays, there are different cytostatic and 
cytotoxic agents used in chemotherapy. They can be divided into different 
classes such as: 
• alkylating agents 
• antitumor metal complexes (e.g. cisplatin, carboplatin) 
• antimetabolites  
• topoisomerase I and II inhibitors 
• hormones and hormone antagonists 
 
Chemotherapy is used for tumors that have metastasized already. It is 
important to destroy as many tumor cells as possible without damaging the 
healthy cells. Most chemotherapeutics act on proliferating cells. This means that 
excessive doses of chemotherapeutics also have an effect on healthy cells. 
[5,6,7] 
 
2.2 Experimental antitumor compounds 
2.2.1 Copper 
Copper is a long known metal. As early as 5000-4000 BC copper was used to 
manufacture tools and played a very important role in the history of mankind as 
a component of bronze.  
Copper belongs to the coin metals, because it is easy to mine and to handle. 
Similar to silver, it has a high conductivity. It is, though, significantly cheaper 
than silver, therefore it is widely used in electric wiring and the like today.  
In the earth’s crust copper is found in 68x10-4 mass%. The natural abundance 
of copper isotopes is given as follows: 63Cu 69.2 % and 65Cu 30.8 %. The 
electron configuration of copper is [Ar]3d104s1 and consequently the preferred 
oxidation states are Cu(I) and more importantly Cu(II).  
Cu(I), cuprous, forms diamagnetic salts and disproportionates in aqueous 
solutions according to the following equation: 
2 Cu(I) (aq) ? Cu(s) + Cu(II) (aq) 
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Cu2O, Cu2S, CuI and complexes thereof are well known and have a low 
solubility in water. In medicine, Fehling’s solution is used to test for sugars in 
urine. For this purpose, CuSO4, tatrate and NaOH are added to reducing sugars 
(such as aldehydes). Cu(II) is reduced to Cu2O, a red compound.  
Cu(II), cupric, is subjected to Jahn-Teller distortions as predicted for octahedral 
d9 ions. In aqueous solution, the [Cu(H2O)6]
+2 ion is formed. Copper(II) sulfate 
and nitrate are fungicides and used as solutions in water.  
In biological systems copper plays an important role, too. It is a structural and 
catalytic cofactor that is involved in important biochemical processes. Copper 
exhibits redox activity due to the two oxidation states (Cu(I), Cu(II)). In these 
two states it prefers different ligands. Cu(II) prefers “harder” ligands such as 
nitrogen or oxygen donors whereas Cu(I) prefers “softer“ ones such as sulfur 
donors. [8,9] 
 
2.2.2 Ruthenium  
Ruthenium is like osmium a member of the platinum-metal group in the periodic 
table. Its electron configuration in the ground state is [Kr]5s14d7. The oxidation 
states vary from -II in Ru(CO)4
2- to +VIII in RuO4, with +III as the most stable 
oxidation state. Ruthenium has 7 natural isotopes (96,98,99,100,101,102,104Ru), and 
99,101Ru are commonly used for NMR-spectroscopic measurements due to their 
favorable magnetic properties. [9,10,11]  
There is a number of interesting, distinct features for the development of 
ruthenium-based antitumor drugs, such as the ability to mimic iron, its 
octahedral coordination geometry, physiological oxidation states ((+II), +III, 
+IV), advantageous ligand exchange rates and well-understood coordination 
chemistry. [12] 
The first ruthenium-based anticancer drugs in clinical trials were NAMI-A and 
KP1019. [13] They are administered intravenously. Consequently, primary 
binding partners are proteins that occur in the blood stream such as transferrin 
and albumin (HAS).  
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Ru(II)/Ru(III) electron transfer does not lead to a change of the coordination 
number and interatomic bond distances, as opposed to Pt(IV) that is reduced to 
Pt(II). This could be one reason for the different mode of action and an 
explanation why KP1019 shows effects on cisplatin-resistant tumors. Most likely 
the activity of NAMI-A and KP1019 derives from a direct coordination of the 
metal to a biological target. This would mean that a reduction to Ru(II) is 
happening. Still, if the metal ion binds to the biological target and this specific 
interaction is responsible for the activity, these compounds can be described as 
functional compounds. [12,13,14,15]  
 
     
Fig. 2 KP1019, indazolium trans-[tetrachlorobis-(1H-indazole)ruthenate(III)] (left) and 
NAMI-A, imidazolium trans-[tetrachloro(dimethylsulfoxi-de)(1H-imidazole)ruthenate(III)] 
(right) [15] 
N
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Cl
Cl H
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O
NH
H
N
Fig. 3 „Generic RAPTA structure Ru(?6-arene)Cl2(pta) with potential sites for modification 
indicated.“ [16] 
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RAPTA-C [Ru(?6-cymene)Cl2(pta)], has been subject to intense research. It has 
been showed that the chloride ligands can be hydrolyzed in aqueous 
environments. In blood plasma the chloride concentration is high enough that 
the ligands will stay coordinated to the complex, but in the cytoplasm they may 
be exchanged. This could be one possible activation pathway. [16] So far, a lot 
of different RAPTA-type compounds were produced. In comparison to other 
antitumor drugs such as cisplatin, RAPTA complexes are less cytotoxic, but 
have a high selectivity for some cancer cell lines, for example TS/A, whereas 
they are harmless for healthy cells. [17]  
 
2.2.3 Osmium 
Osmium is a noble metal. Like ruthenium it belongs to the platinum-metal group. 
It was discovered 1804 by S. Tennant. Its ground state electron configuration is 
[Xe]4f146s25d5 and the possible oxidation states range from -II to +VIII as in the 
case of ruthenium, but the preferred state is +IV. Again, there are 7 natural 
isotopes (184,186,187,188,189,190,192Os) and two of them 187,189Os are commonly 
employed in NMR-spectroscopic measurements. [18]  
Osmium(II) arene complexes were reported to be cytotoxic in cancer cells. [19] 
The ligand exchange rates of Os(II) and Ru(II) are different, as the Os(II) and 
Os(III) complexes are kinetically more inert than their ruthenium analogues. [20] 
How its organometallic complexes behave in aqueous environments is not yet 
fully understood. [22] It was shown that osmium(II) arene complexes with an 
N,N-chelating ligand are hydrolyzed more slowly than those with an O,O-
chelating ligand. The hydrolysis barrier for [Os(?6-biphenyl)(en)Cl]+ (N,N-
chelating) is higher than for [Os(?6-p-cym)(acac)Cl] (O,O-chelating), for 
example, and in comparison to Ru(II) analogues of [Os(?6-biphenyl)(en)Cl]+ the 
osmium analogue hydrolyses 40 times slower at physiological pH than the 
corresponding osmium complex. Hence, not only the metals in the complexes 
are important for activity and hydrolysis, but the chelating ligand plays a major 
role as well. [20,21,22]  
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2.2.4 Indoloquinolines 
Indolo-[3,2-c]quinolines are composed of an indole and a quinolin-2(1H)-one 
moiety. 
 
The indole scaffold is a structural feature of some clinically used anticancer 
drugs e.g. vinblastine [23 ] and vincristine [24 ], and quinolin-2(1H)-one is 
contained in many biologically active compounds. [ 25 ] Isocryptolepine or 
cryptolepin, indoloquinoline derivates that can be isolated from Cryptolepis 
sanguinolenta, are used in traditional medicine for malaria treatment or other 
diseases. [26]  
Indolo-[3,2-c]quinolin-2(1H)-one showed an inhibitory activity (GI50 value of 
19.0 ?M) in a human tumor cell line screen conducted by the US National 
Cancer Institute. [27] Different indoloquinoline derivatives have shown biological 
activity in cancer. [25,27,28] 
To improve solubility of derivatives and to increase anti-proliferative properties, 
metal-complexes are formed. [25,35] The heteroaromatic system of the 
complex is planar and has a high potential to intercalate into DNA. [29] 
 
2.2.5 Test compounds 
As seen in Fig. 5 and Fig. 6 two different groups of metal compounds were 
investigated. Complexes of indolo[3,2-c]benzazepines, also named as 
Paullones, and related indolo[3,2-c]quinolines with different substitutions and 
copper(II) as the metal center were tested. The main difference is found in the 
six- or seven-membered ring of the ligands, implying that indoloquinolines have 
 
Fig. 4 Structure of indole, quinoline-2(1H)-one components and indolo[3,2-c]quinolin-2(1H)-
one 
N
H
N
H O
H
N
HN
O
indole quinoline - 2(1H)-one indolo[3,2-c]quinolin-2(1H)-one
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a planar structure whereas Paullones are folded. Additionally, substituents in 
position 8 and 14 were varied. Due to bad solubility of the corresponding 
ligands, the ligands themselves could not be tested. This shows that 
complexation results in higher solubility. 
Fig. 5 Copper(II) compounds with modified indoloquinoline and Paullone ligands 
 
The second group of tested compounds was ruthenium(II) (7a, 8a, 9a) and 
osmium(II) (7b, 8b, 9b) complexes with modified indoloquinoline ligands. These 
complexes are the first ones coordinated via position 2 of the indoloquinoline 
backbone. In the case of 9a,b an underivatized lactam moiety is present. This 
was found to be necessary for efficient cdk inhibition in the case of the 
Paullones. [30] 
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Fig. 6 Ruthenium(II) and osmium(II) compounds with various indoloquinoline ligands 
 
2.3 Biological studies of antitumor compounds 
2.3.1 Cytotoxicity Analysis 
For testing the cytotoxic activity of new potential anticancer drugs the so-called 
colorimetric MTT assay is used (MTT stands for 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide). In principle, the assay is based on the 
reducing properties of living cells. [31] 
 
Fig. 7 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide reduced to the formazan 
product 
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MTT is membrane impermeable and therefore the uptake happens via 
endocytosis. The transport of the formazan to the cell surface takes place 
through exocytosis. [32] 
After treatment of the cells with the compound to be tested, the MTT reagent, a 
yellow, water-soluble tetrazolium dye, is added to the cells. In living cells the 
tetrazolium salt is reduced to a purple-colored formazan product. The formed 
formazan product is water insoluble and has to be solubilised in another solvent 
such as DMSO. The optical density (at 550 nm and at 690 nm reference 
wavelength) of the formzan product is measured on a spectrophotometer, and 
consequently the amount of viable cells can be determined, because the 
relationship between the formazan product and the number of living cells is 
linear. [33,34,35]  
 
 
Fig. 8 MTT plates, description of the procedure. (top left) medium with treated cells, (top right) 
added RPMI/MTT solution, (bottom left) after 4 h incubation, formazan crystals are formed, 
(bottom right) dilution with DMSO, different concentration of the formazan can be seen. 
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The IC50 (50% inhibition concentration) is an index number used to quantify the 
anti-proliferative activity. The IC50 is defined as the concentration of the agent 
that results in a 50% lower cell number compared to the untreated control. [36] 
This value is calculated from the concentration-effect curve of the treated cells 
by interpolation. 
 
2.3.2 Cell Cycle Analysis 
The cell cycle (cf. Fig. 9) is the series of events that takes place in a cell that 
ultimately leads to its duplication and division. There are two major phases of 
the cell cycle: the interphase and the mitosis or M phase. The interphase is 
divided into three subphases called G1, S and G2 phase where G stands for 
gap. These gap phases give the cell more time to grow and monitor the internal 
and external environments. During the S phase, DNA replication occurs. In the 
M phase, also named mitosis, nuclear division and cytokinesis proceeds.  
 
Fig. 9 The four phases of the cell cycle [37] 
 
In the cell cycle there are checkpoints that are a part of the cell cycle control 
system. These checkpoints trigger mitosis, cytokinesis and DNA replication. If 
the environment is not favorable, DNA does not replicate or the chromosomes 
do not attach to the mitotic spindle, the cell is going into a cell cycle arrest. 
14 Introduction 
For cell cycle analysis, flow cytometry is 
used to measure in which phase of the 
cell cycle the cells are. Thousands of cells 
can be measured within a few seconds or 
minutes using this method. For this 
purpose, the cells are stained with a 
fluorescent, DNA intercalating dye such 
as propidium iodide (cf. Fig. 10). [38] 
 
In the different phases of the cell cycle, 
different amounts of DNA are present in the 
cell. There is twice as much DNA, for 
example, in the G2/M phase than in G1. Most 
methods cannot discriminate between G2 and 
M phase, though. In the S phase there is an 
intermediate amount of DNA. The amount of 
the DNA is proportional to the amount of 
fluorescence. The histogram shows two peaks 
of cells in G1 and G2/M, hence. In between 
these two peaks the cells in S phase are 
found (cf. Fig. 11). Changes in the cell cycle 
are observed by comparison to an untreated 
control. [37,39] 
 
2.3.3 Intercalation Assay 
This assay is also known as the methyl green assay. Methyl green [40] 
(nowadays also ethyl green is used) (cf. Fig. 12) binds to DNA and has an 
absorption maximum at 642 nm. [25] It was shown that methyl green is a major 
groove binder that binds to poly[d(A-T)]. [41] It is important to know that methyl 
green is just interacting with polymerized DNA, because depolymerized DNA 
(by e.g. heating) cannot protect methyl green in neutral pH. The methyl green-
 
Fig. 11 Flow cytometric 
histogram of analysis of cellulat 
DNA content 
?
 
Fig. 10 Propidium Iodide 
NH2
H2N
N N
I I
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DNA complex is stable at pH > 5. [42] Free methyl green shows no absorption 
because it forms a colorless carbinol. [43]  
If a DNA-intercalating compound inter-
acts or binds to the DNA-methyl green 
complex, it leads to a displacement and 
consequently to a release of methyl 
green.  
As a result, the optical density in the 
sample decreases. Partial planarity or at 
least a hydrogen bond should exist for 
functional intercalations. [44]  
The methyl green assay and his usefulness has been documented in numerous 
papers. A lot of different DNA-complexing substances were tested and their 
biochemical or biological activity e.g. to antibacterial properties as well as 
immunosuppressive activity, were correlated to methyl green displacement. [45] 
 
2.3.4 Detection of Apoptosis 
2.3.4.1 Western blotting 
Western blotting or immunoblotting is a method that allows the transfer of 
proteins onto a nitrocellulose-membrane for further identification or 
quantification by detection with antibodies, for example.  
The method can be described consisting of three main parts: 
• Gel electrophoresis 
• Transfer to membrane 
• Detection 
Sample preparation in the beginning is one of the most important steps. The 
proteins must not be fragmented or be destroyed by proteases.  
Separation of proteins in the sample is accomplished by discontinuous SDS-
PAGE (polyacrylamid-gel electrophoresis) where the anionic detergent SDS 
destroys the hydrophobic interactions of the protein and additionally charges the 
 
Fig. 12 4-((4-(Dimethylamino)phenyl)(4-
(dimethyliminio) cyclohexa-2,5-dien-1-
ylidene)methyl)- N-ethyl-N,N-dimethyl-
anilinium-bromide-chloride [40] 
N N
N
Br
Cl
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protein negatively. As a result, the proteins are separated depending on their 
respective molecular masses. Discontinuously means that first the proteins are 
added into a stacking gel, then they are focused with low voltage and after 
entering the separation part of the gel, voltage is increased.  
After that, transfer onto the membrane is done via Semi-dry blotting. Semi-dry 
blotting procedure resembles the wet blotting. The main differences are that 
less buffer is needed and the device works horizontally instead of vertically. The 
assembly of a sandwich in a semi-dry blot is shown in Fig. 13.  
 
 
Fig. 13 Sandwich assembly of a semi-dry blot 
 
After the transfer, the membrane is blocked with blocking proteins such as BSA 
or by using milk in order to prevent unspecific binding of the detection 
antibodies. At least two antibodies are used: a primary antibody against the 
protein and a secondary antibody against the primary. The second one is 
conjugated to an enzyme e.g. HRP or labeled with a fluorescence marker. [46] 
The following luminescence or fluorescence measurement can be done 
employing CCD-Imaging systems or the like. 
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2.3.4.2 PARP 
PARP (poly(ADP-ribose)polymerase) is a 116 kDa Zn-finger nuclear protein that 
is involved in DNA repair response. It is activated by DNA strand breaks and 
uses ? NAD+ to catalyze (ADP-ribose) polymers on nuclear proteins. PARP 
cleavage by caspase-3 or caspase-7 plays an important role early in apoptosis. 
At first PARP is accumulated in the early apoptotic cells and then it is cleaved. 
This happens between Asp214 and Gly215. Hence, the resulting fragments weigh 
89 kDa (from the carboxyl-terminal catalytic domain) and 24 kDa (from amino-
terminal DNA binding domain). This cleavage inactivates the poly(ADP-
ribosylation) process and PARP is inactive towards DNA damage, 
consequently. [47,48,49]  
 
Fig. 14 Apoptosis cascade and cleavages of PARP [48] 
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3 Materials and Methods 
3.1 Cell Lines  
 
 
 
 
 
 
 
Fig. 16 CH1 (ovarian carcinoma), kindly provided by Lloyd R. Kelland, CRC 
Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, U.K. 
Fig. 15 SW480 (colon carcinoma) kindly provided by Brigitte Marian, Institute of 
Cancer Research Department of Medicine I, Medical University Vienna, Austria  
Fig. 17 A549 (non-small cell lung cancer) kindly provided by Brigitte Marian, 
Institute of Cancer Research Department of Medicine I, Medical University 
Vienna, Austria 
 
Fig. 17 A549 cells  
 
Fig. 16 CH1 cells 
 
Fig. 15 SW480 cells 
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3.2 Media 
3.2.1 Minimal Essential Medium (MEM)  
Minimum Essential Medium Eagle (Sigma Aldrich, M2279) supplemented 
with: 
• 10% heat-inactivated fetal bovine serum (FSB Fetal Bovine Serum, 
GIBCO 10270, invitrogen) 
• 1 mM sodium pyruvate (Sodium Pyruvate 100 mM Solution, Sigma 
Aldrich, S8636) 
• 1% non-essential amino acid (non-essential amino acid solution 100x – 
Sigma Aldrich, M7145) 
• 4 mM L-glutamine (L-Glutamine 200 mM, Sigma Aldrich, G7513) 
 
3.2.2 RPMI 1640 medium supplemented with: 
RPMI 1640 Medium, HEPES Modification (Sigma Aldrich, R5886) 
supplemented with: 
• 10% heat-inactivated fetal bovine serum (FSB Fetal Bovine Serum, 
GIBCO 10270, invitrogen) 
• 4 mM L-glutamine (L-Glutamine 200 mM, Sigma Aldrich, G7513) 
 
 
3.3 Buffer 
3.3.1 PBS  
Dulbecco’s Phosphate Buffered Saline (Sigma Aldrich, D8537) 
 
3.3.2 HSF Buffer (hypotonic fluorochrome solution)  
• 0.1% (v/v) Triton X-100 
• 0.1% (w/v) Sodium Citrate 
• PBS (Dulbecco’s Phosphate Buffered Saline (Sigma Aldrich, D8537)) 
 
3.3.3 RIPA Buffer (Radio Immuno Precipitation Assay buffer)  
• 150 mM sodium chloride  
• 1.0% Triton X-100  
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• 0.5% sodium deoxycholate  
• 0.1% SDS (sodium dodecyl sulfate)  
• 50 mM Tris, pH 8.0 
 
3.3.4 Electrophoresis Buffer 10x 
• 30.3 g Tris 
• 144.13 g glycin 
• 10 g SDS 
• 1 l milli Q water 
 
3.3.5 Transfer Buffer 10x 
• 30.3 g Tris/HCl 
• 144.13 g Glycin 
• 1 l milli Q water 
• pH 8.3  
 
3.3.6 Transfer Buffer 1x 
• 100 ml Transfer Buffer 10x  
• 200 ml Methanol 
• 700 ml milli Q water 
 
3.3.7 Blocking Buffer 
• milk 5%, TBST (Tween 0.1%) (Blotting Grade Blocker Non-Fat Dry Milk, 
Bio-Rad Laboratories, 170-6404)?
• BSA 5%, TBST (Tween 0.1%) (Albumin, from bovine serum (Sigma 
Aldrich, A7906)?
?
3.3.8 Stripping Buffer 
• 15 g glycine  
• 1 g SDS  
• 10 ml Tween 20 (polyoxethylene sorbitan monolaurate, Bio-Rad 
Laboratories, 170-6531)  
• pH to 2.2  
• diluted to 1 l with milli Q water 
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3.3.9 TBS 10x 
• 24,2 g Tris  
• 80 g NaCl 
• adjusted to pH 7,6 with HCl 
• diluted to 1 l with milli Q water 
 
3.3.10 TBST 1x 
• 100 ml 10xTBS  
• 1 ml Tween-20 
• diluted to 1 l with milli Q water 
 
3.3.11 Laemmli 6x Buffer 
• 12% SDS 
• 30% 2-mercaptoethanol 
• 60% glycerol 
• 0.012% bromophenol blue 
• 0.375 M Tris HCl 
• pH 6.8 
 
 
3.4 Diverse Reagents 
• 0.25% Trypsin – EDTA Solution (Sigma Aldrich, T4049) 
• Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific, 
#34080) 
• Deocyribonucleic acid (DNA) Sodium Salt from Salmon Testes (Sigma 
Aldrich D-1626) 
• Acrylamid/bis-Acrylamid, 30% Solution Electrophoresis Reagent (Sigma 
Aldrich)  
• N,N,N’,N’,-Tetramethylethylenediamine (Sigma Aldrich, T9281) 
• Sodium dodecyl sulfate (Sigma Aldrich, L4390) 
• Thiazolyl Blue Tetrazolium Bromide, approx. 98% TLC (Sigma Aldrich, 
M2128) 
• For MTT-Assay, 5 mg/ml in PBS 
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• Ammonium persulfate, for electrophoresis, ? 98% (Sigma Aldrich, 
A3678) 
• Propidium iodide (Fluka, 81845) 
• Ethidium bromide (Serva, 21251) 
 
 
3.5 Cell Culture Conditions 
All cells were grown in 75 cm2 culture flasks as adherent monolayer cultures in 
MEM (Minimum Essential Medium) without antibiotics at 37 °C under a moist 
atmosphere containing 5% CO2 and 95% air.  
 
3.6 Cytotoxicity Assay 
Cytotoxicity of all compounds was determined by using the colorimetric MTT 
assay (3-/4,5-dimethyl-2-thiazolyl)-2,5-diphenal-2H-tetrazolium bromide). After 
harvesting by trypsinization cells were seeded into 96-well micro culture plates 
(100 ?L/well and three replicates per concentration). For the copper complexes, 
different cell densities were used as follows: CH1 - 1.5 x 103 cells/well, SW480 - 
2.5 x 103 cells/well and A549 - 4.0 x 103 cells/well. For the ruthenium- and 
osmium-based complexes, CH1 cells were seeded in a density of 1.0 x 103 
cells/well; the other cell lines were used with the same densities as used for the 
copper compounds. These densities were chosen to ensure exponential growth 
of the untreated controls over the whole time of experiment. After 24 h the test 
compounds were dissolved in DMSO, mixed with medium to a maximum DMSO 
concentration of 1% v/v, serially diluted and added to the plates in volumes of 
100 ?L/well. For the highest concentration (80 ?M) of Ru and Os compounds, 
medium was removed and 200 ?l of medium with the final concentration of the 
test compound was added. Therefore the maximum DMSO concentration was 
0.5% v/v. After continuous exposure for 96 h at 37 °C and under 5% CO2, the 
medium was replaced by 100 ?L/well RPMI 1640 medium and 20 ?L/well MTT 
solution. After 4 h incubation (same conditions as before) the medium was 
removed and the formed formazan product was dissolved in DMSO (150 
?L/well). With a 96-well micro plate reader (Tecan Spectra Classic) optical 
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densities at 550 nm (690 nm reference wavelength) were measured. The 50% 
inhibitory concentrations (IC50) were calculated from the concentration-effect 
curves by interpolation. The tests were repeated at least three times in 
independent experiments. [35]  
 
3.7 Cell Cycle Analysis 
For this assay A549 cells were harvested by trypsinization and 3 x 105 cells in 2 
ml/well were seeded into 6-well plates. After 24 h incubation at 37 °C and 5% 
CO2, the test compounds, dissolved in DMSO, were added directly to the 
plates, with a maximum concentration of 1% v/v DMSO. After continuous 
incubation for 24 h (under same conditions as before) the cells were washed 
with PBS and trypsinized. Trypsinization was stopped with MEM, the cells were 
centrifuged (1200 rpm, 3 min) and the supernatant was discarded. Then the 
cells were washed with PBS again and resuspended in 300 ?L PI/HSF-buffer 
with a concentration of 50 ?g PI/ml. After incubation over night/weekend in the 
fridge (4 °C) in the dark, 1x104 cells were measured by flow cytometry on a BD 
FACS Calibur instrument. [50,51]  
 
3.8 DNA Intercalation Assay 
dsDNA (from salmon testes) solution (10 mg/ml) was prepared in MEM one day 
before usage and shook at 37 °C until it was a highly viscous liquid. This stock 
solution was further diluted 1:100 in MEM. Medium was used, because earlier 
test (not reported here) had shown, that with the standard procedure (using milli 
Q water to dilute DNA and PBS for sample preparation) these compounds build 
a kind of jelly-looking fallout, so the sample could not be measured and very 
bad reproducibility was observed. Methyl green was prepared in milli Q water (1 
mg/ml). The samples were prepared as shown in Tab. 1. To achieve the same 
concentration of DMSO, additional pure DMSO was added to gain an overall 
amount of 1% in every sample. First the samples were prepared without the 
drugs and incubated for 1 h at 37 °C in the dark to allow methyl green to 
intercalation into the DNA. 
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Tab. 1 Composition of samples for the methyl green assay compounds were diluted and 1% 
DMSO was added to every sample. 
 
 
 
DNA [?l] 
(100 ?g/ml) 
Methyl green [?l] 
(1 mg/ml) 
MEM [?l] Compound 
[?l] 
Final 
compound 
concentration 
[?M] 
1 Blank 0 40 1940 20 0 
2 Control 1000 40 940 20 0 
3 
Pos. 
Control 1 
1000 40 940 20 100 
4 
Pos. 
Control 2 
1000 40 940 20 50 
5 Sample 1 1000 40 940 20 50 
 
Subsequently the compounds and DMSO were added and incubated for 2 
hours in the dark at 37 °C. EtBr was used as positive control due to the 
knowledge that EtBr is a DNA intercalator. Additionally KP1779, a strongly 
intercalating indoloquinoline-complex with osmium as metal center, was used 
as a second positive control. During this time the test substances can interact 
with DNA to replace the methyl green. Aliquots of 300 ?l of the sample solution 
were filled into a 96-well plate (three replicates per sample), and the absorption 
was measured at 642 nm with a Bio-Tek (Synergy HT) reader. 
 
3.9 Western Blot 
For the Western blot experiments, 3 x 105 CH1 cells/well were seeded into 6-
well plates. After 24 h the test-compounds were added in different 
concentrations. After different incubation times (12 h, 16 h, 18 h, 24 h) the 
medium was removed and the cells were washed with cold PBS. Afterwards the 
cells were lysed with RIPA buffer (with 1:100 protease-inhibitor cocktail P8340 
Sigma added), scraped down with a rubber policeman and transferred into a 
cooled Eppendorf tube. The lysates were vortexed and gentle shaken for 20-30 
min, afterwards they were centrifuged at 14 000 rpm for 10 min at 4 °C. The 
supernatant was removed and added to fresh cooled Eppendorf tubes which 
were then stored at -80 °C.  
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For the gel electrophoresis, 5% SDS PAGE stacking gel and 9% SDS-PAGE 
separation gels (1 mm) were prepared. (SDS PAGE gels containing: 30% 
polyacrylamide, TEMED, 10% SDS, H2O, 10% APS, Tris (1.5 M, pH 8.8 
separating gel, 1 M, pH 6.8 stacking gel). Before lysates were loaded onto the 
gel, they were mixed with Laemmli 6x Loading Buffer and heated 5 min at 95 
°C. The marker P 7711 (ColorPlus Prestained Protein Ladder, Broad Range 
(10-230 kDa), New England BioLabs) was used. With 80 V the proteins were 
focused in the stacking gel, and subsequently they were separated with higher 
voltage of 120-160 V.  
With semi-dry blotting the proteins were transferred from the gel to the 
nitrocellulose-membrane. The run took 1 h 30 min with 75-80 mA/membrane. 
Blocking was done with 5% milk/TBST for at least 1 h. Afterwards the 
membrane was incubated with the primary polyclonal antibody PARP (#9542, 
Cell Signaling Technology) 1:1000 dilution, gentle shaking over night at 4 °C. 
After three washing steps (each 5 min) with TBST, the membrane was 
incubated with the secondary antibody (Anti-rabbit IgG, HRP-linked Antibody, 
#7074, Cell Signaling Technology) 1:1000 dilution, for 1 h. Then the membrane 
was washed three times with TBST (5 min each), chemiluminescent substrate 
was added and incubated for 5 min. Measurement was done by the CCD-
imaging system, Fusion FX7.  
After the measurement, the antibodies were removed by stripping. Mild stripping 
was done as described in [52], furthermore 5% BSA/TBST was used for 
blocking over a period of 1 h. Then primary antibody against ?-actin (b-Actin 
(13E5) Rabbit mAb, Cell Signaling Technology; 1:2000 dilution) was added and 
the membrane incubated for at least 1 h. Again the membrane was washed with 
TBST three times (5 min each), and the secondary antibody (Anti-rabbit IgG, 
HRP-linked Antibody, #7074, Cell Signaling Technology; 1:1000 dilution) was 
added and incubated for 1 h. The washing process was repeated and 
chemiluminescent substrate was added and the membrane incubated for 5 min. 
Measurement was done by the CCD-imaging system, Fusion FX7. 
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4 Results and Discussion 
4.1 Cytotoxicity Assay 
The cytotoxicity of the compounds was determined using the colorimetric MTT 
assay in the described cell lines. Some compounds showed IC50 values in the 
range of 10-8 to 10-6 M (Tab. 2). The copper(II) complexes showed a higher 
sensitivity in all cell lines than the ruthenium(II) and osmium(II) complexes. The 
corresponding uncomplexed ligands could not be tested due to their insufficient 
solubility. A549, the most chemo-resistant cell line in the experiment, was the 
least sensitive one for all the tested compounds, whereas in CH1, a chemo-
sensitive cell line, IC50 values of all compounds within the applicable range of 
concentrations were detected. 
The following structure-activity relationships of the copper(II) complexes were 
observed: A substitution at position 8 with a methyl (2a), chloro (3a) or bromo 
(4a) group has nearly no impact on the cytotoxicity compared to compound 1a 
that has no substituent in this position. Adding a methyl group at position 14 
results in a dramatic enhancement of cytotoxicity, indicating that this position is 
crucial responsible for the activity of the compounds. In A549 and CH1 cells, 
IC50 values are about 10 times lower, and in SW480 cells a 50-fold increase of 
cytotoxicity was found, e.g. compound 1b (Fig. 18). The IC50 values of 2b, 3b 
and 4b are one order of magnitude lower than those of the analogues 2a, 3a 
and 4a. This approves, the irrelevance of methyl, chloro and bromo 
substitutions at position 8 as well as the impact of the methyl substitution at 
position 14. [35] 
Copper(II) complexes with Paullone ligands (5, 6a and 6b) were compared to 
their analogues of indoloquinoline ligands (1b, 4a and 4b). The main difference 
of these ligands is located in the seven membered azepine ring instead of the 
planar six membered ring found in indoloquinolines. [35] 
Comparison between indoloquinoline and Paullone complexes of ruthenium(II) 
and osmium(II) has been reported in literature. [25] The comparison of 4b with 
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6b and 1b with 5 in SW480 cells showed the highest difference with a 6 and 9 
times higher cytotoxicity of the indoloquinoline complexes (Fig. 19). In contrast, 
4a and 6a have a comparable cytotoxicity in all three cell lines. There can be 
several reasons for the generally smaller differences as well as the generally 
higher cytotoxicity of the copper(II) complexes. One may be related to the 
different central metal (copper(II) instead of ruthenium(II) or osmium(II)) or the 
different side chain of the ligands and with it the consequences for coordination 
of the metal or a combination of both. [35] 
For ruthenium(II) and osmium(II) complexes IC50 values in the micromolar range 
were found. A549 was the least sensitive cell line for all the tested compounds. 
For three of them (8b, 9a, 9b), it was not possible to determine IC50 values       
(> 80 ?M) due to the insufficient solubility in medium. Furthermore no IC50 
values in SW480 could be determined for 9a. Some compounds showed a four-
fold increase of cytotoxicity (7a) in SW480 and up to forty times (8a) lower IC50 
values in CH1 than in A549.  
Comparison of the ruthenium(II) with the osmium(II) complexes revealed the 
following relationships: In general CH1 is 9-40 times more sensitive than the cell 
line A549, and for all tested compounds IC50 values were reached with 
applicable concentrations. In A549 cells, ruthenium complexes (7a, 8a) are 
more active than osmium complexes (7b, 8b). In CH1 and SW480 cells, 
ruthenium complexes are at least twice up to four times more active than 
osmium complexes except for the pair 9a and 9b, of which the osmium complex 
is more active. A reason could be the structural difference at the lactam unit. 
The ruthenium compound 9a is the least active one of all tested compounds. 7a 
compared with 8a (chloro substituent at position 6) showed twice as high 
activity in A549 and SW480 cells, whereas in CH1 cells 7a is less active. 7b 
and 8b give a similar picture, except that in SW480 cells the IC50 values are 
nearly the same.  
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Tab. 2 50% inhibitory concentrations (means ± standard deviations from at least three 
independent experiments), as obtained by the MTT assay using exposure times of 96 h.  
 
IC50 (?M), 96 h 
compound A549 SW480 CH1 
          
1a 1.72  ± 0.03 1.3  ± 0.1 0.40  ± 0.07 
1b 0.18  ± 0.04 0.024  ± 0.001 0.030  ± 0.005 
2a 1.7  ± 0.1 0.75  ± 0.04 0.33  ± 0.07 
2b 0.14  ± 0.01 0.024  ± 0.002 0.026  ± 0.006 
3a 1.4  ± 0.3 0.64  ± 0.11 0.41  ± 0.05 
3b 0.23  ± 0.01 0.049  ± 0.003 0.065  ± 0.012 
4a 1.6  ± 0.1 0.47  ± 0.03 0.36  ± 0.03 
4b 0.20  ± 0.03 0.032  ± 0.004 0.052  ± 0.008 
5 0.67  ± 0.15 0.21  ± 0.04 0.064  ± 0.015 
6a 1.28  ± 0.03 0.40  ± 0.04 0.28  ± 0.03 
6b 0.43  ± 0.03 0.18  ± 0.02 0.080  ± 0.005 
7a 27  ± 3 7.03  ± 1.66 3.2  ± 0.3 
7b 53  ± 9 28  ± 6 9.9  ± 2.1 
8a 51  ± 2 17  ± 3 1.3  ± 0.5 
8b > 80 25  ± 2 3.1  ± 0.8 
9a > 80 > 80 20  ± 2 
9b > 80 48  ± 5 7.9  ± 0.9 
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Fig. 18 Concentration-effect curves of copper-indoloquinoline complexes 1a, 1b, 2a and 2b in 
the human cancer cell lines A549 (A), CH1 (B), SW480 (C), indicating the different impact of 
methyl substitution depending on the position. [35] 
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Fig. 19 Concentration-effect curves of copper-indoloquinoline complexes 1b and 4b in 
comparison with the corresponding Paullone complexes 5 and 6b in the human cancer cell lines 
A549 (D), CH1 (E), SW480 (F), all determined by the MTT assay using continuous exposure for 
96 h. [35] 
 
Results and Discussion 31 
 
 
Fig. 20 Concentration-effect curves of copper-indoloquinoline complexes 3a, 3b, 4a and 
copper-Paullone complex 6a in the human cancer cell lines A549 (G), CH1 (H), SW480 (I), 
determined by the MTT assay using continuous exposure for 96 h. [35] 
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Fig. 21 Concentration-effect curves of ruthenium- and osmium- indoloquinoline complexes 7a, 
7b, 8a, 8b, 9a and 9b in the human cancer cell lines A549 (J), CH1 (K), SW480 (L), determined 
by the MTT assay using continuous exposure for 96 h. 
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4.2 Cell Cycle Analysis 
Filak et al. [29] stated that indoloquinolines show effect on the cell cycle. They 
observed that the complexes lead to an arrest in the G2/M phase and inhibition 
of cdk2/cyclin E was found in a cell free setting.  
Based on this fact, the activity on the cell cycle of the copper complexes 1a, 1b, 
2a, and 2b was tested. Incubation time (24 h) and concentrations were chosen 
in such a way that apoptosis was avoided.  
As seen in Fig. 22 and Fig. 23, none of the tested compounds showed a 
significant effect on the cell cycle. The sub G0 peak or the debris (results not 
shown) was nearly the same in all measured samples, with an average amount 
of 2%, indicating that the chosen concentrations of the compounds do not 
cause cell death to a noteworthy extent. Because of the lack of cell cycle effects 
we did not expect a relevant effect on cdk activity. In fact, these observations 
strongly argue against cdks as the critical target of these complexes. This was 
the reason why cdk inhibition was not studied.  
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Fig. 22 Concentration-effect curves of complexes 1a (A) and 1b (B) in the human cancer cell 
line A549, determined by cell cycle analysis using continuous exposure for 24h 
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Fig. 23 Concentration-effect curves of complexes 2a (C) and 2b (D) in the human cancer cell 
line A549, determined by cell cycle analysis using continuous exposure for 24h 
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4.3 Intercalation 
As reported in Filak et al. [22], indoloquinolines show a high potential to inter-
calate into dsDNA. Due to the reported results, intercalation ability of 
compounds 1a-2b was expected. Ethidium bromide (EtBr) and [(?6-p-Cymene)-
OsII(L2)Cl]Cl,(?6-p-cymene)(?N’-[11H-indolo[3,2-c]quinolin-6-ylidene]-?N,N-
dimethylethane-1,2-diamine)chloridoosmium(II)chloride (KP1779), a strongly 
DNA intercalating compound of similar structural form, were used as positive 
controls to prove that the change of the solvent from PBS to medium does not 
affect the performance of the method. As shown in Fig. 23, methyl green 
displacement of about 90% by EtBr as well as intercalation by KP1779 
comparable to Filak et al. were found. These results confirm that the method is 
not affected. To exclude effects caused by the usage of DMSO as substance 
solvent, the same amount of DMSO was added to every sample. Hence, no 
errors should be produced by that. 
For the copper compounds, no reliable and meaningful degree of intercalation 
was found. Even some rather mind negative values can be seen in some cases. 
These might suggest a slight enhancement of methyl green binding to DNA, but 
might as well be mere artifacts of unknown come. 
 
 
Fig. 24 Replacement of methyl green of 1a, 1b, 2a, 2b, KP1779 and EtBr at different 
concentrations  
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Although the structurally related compound KP1779 is showing intercalating 
properties, the copper(II) indoloquinolines are not active in the methyl green 
assay. The comparison of KP1779 and the tested copper compounds shows 
different coordination sites of the metals. In the case of copper(II) complexes, 
copper is coordinated via the quinoline nitrogen to the indoloquinoline moiety, 
whereas in KP1779 osmium(II) is coordinated only via the side chain of the 
ligand. As quinoline is the potential intercalation site, [53] it seem that the 
coordination of copper is hindrance enough that an intercalation is not possible 
any longer. 
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4.4 Western Blot 
For Western blot analysis two copper(II) compounds 1a and 1b were examined. 
1a is the copper(II) complex with an indoloquinoline ligand lacking substituents 
in position 8 and 14, and 1b is the analogue with a methyl substituent at 
position 14. MTT cytotoxicity test showed that this substitution results in strongly 
cytotoxicity (Tab. 2). These compounds were chosen to determine if apoptosis 
is induced via a pathway involving PARP/cleaved PARP. For Western blotting, 
treated CH1 cells were used (IC50 values of 0.40 ± 0.07 ?M for 1a and 0.030 ± 
0.005 ?M for 1b).  
In a first experiment, cells were treated with concentrations of 0.2-2 ?M for 1a 
and 0.05-1 ?M for 1b over 24 h. With increasing concentrations of the 
compounds the intensities of the PARP bands are decreasing, but surprisingly 
no cleaved PARP was observed Fig. 25. To control that comparable protein 
amounts were added onto the gel, ?-actin was used as loading control. Actin is 
omnipresent in the cell and the ?-form is also known as cytoplasmic actin [54], 
furthermore under apoptotic conditions, actin is degraded.[55] The ?-actin 
control illustrates that less proteins were added in samples treated with the 
highest concentration, which seems to be too cytotoxic.  
 
Fig. 25 Detection of PARP (116 kDa), and cleaved PARP (89 kDa) by Western blotting, after 
continuous exposure for 24 h with 1a and 1b. Control bands of ?-actin at 45 kDa.  
 
In the second experiment, the incubation time was reduced and the 
concentrations of the compounds were increased. After 18 h cleaved PARP 
was found in the case of 1a treatment nearly in every concentration and in case 
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of 1b at least in one (1 ?M), but again the loaded protein concentrations were 
not equal. ?-actin and PARP could not be detected in samples from cells 
treated with the highest concentration of 1b, however reduced amounts of 
PARP were detected in the case of the two highest concentrations of 1a and in 
2 ?M and 3 ?M of 1b (Fig. 26). 
 
 
Fig. 26 Detection of PARP (116 kDa), and cleaved PARP (89 kDa) by Western Blotting, after 
continuous exposure for 18 h with 1a and 1b. Control bands of ?-actin at 45 kDa. 
 
In the next experiment the incubation time was reduced from 18 h to 12 h using 
the same concentrations of 1a and 1b. The results were not encouraging, 
nearly no cleaved PARP was found, which could be an evidence that apoptosis 
has not started after 12 h (Fig. 27). 
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Fig. 27 Detection of PARP (116 kDa), and cleaved PARP (89 kDa) by Western blotting, after 
continuous exposure for 12 h with 1a and 1b.  
 
As a consequence the incubation time was increased to 16 h with highest 
concentration of 4 ?M for 1a and 2 ?M for 1b. Fig. 28 shows that cleavage of 
PARP occurred and ?-actin bands indicate that the protein concentration was 
the same for all concentrations.  
 
 
Fig. 28 Detection of PARP (116 kDa), and cleaved PARP (89 kDa) by Western blotting, after 
continuous exposure for 16 h with 1a and 1b. Control bands of ?-actin at 45 kDa. 
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As a final conclusion of the Western blot analysis, the compounds 1a and 1b 
induce apoptosis via a pathway involving PARP/cleaved PARP. The incubation 
time and the concentrations are critical factors for induction of apoptosis. 
Different protein concentrations are caused by too long incubation or high 
concentrations. The optimal conditions for these compounds were found after 
16 h incubation with the described concentrations.  
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5 Conclusions 
Copper(II), ruthenium(II) and osmium(II) complexes with modified indolo-
quinoline ligands have been tested for their antitumor efficiency in vitro, by use 
of the following techniques: cytotoxicity tests, cell cycle analysis, intercalation 
experiments and Western blot studies. 
All copper(II) compounds exhibited high cytotoxic effects in all tested cell lines, 
furthermore IC50 values down to micromolar and nanomolar range have been 
found. In contrast to Filak et al. [25], the expected cytotoxic activity of the 
ruthenium(II) and osmium(II) complexes was not observed most likely as a 
consequence of the altered substitution pattern of the ligands. 
Due to the encouraging results of the copper(II) compounds, cell cycle analysis 
and intercalation experiments with compounds 1a, 1b, 2a and 2b were 
performed. Previous studies [25] demonstrated that indoloquinolines show an 
effect on the cell cycle, leading to a G2/M arrest, and a high extend of 
intercalation (80% replacement of methyl green) was detected. As a 
consequence, similar results for the copper complexes were expected. 
However, no effects on the cell cycle and no intercalating properties were 
found. These data indicate that perhaps cdks are not the crucial target and 
maybe other DNA interactions with these new compounds are playing an 
important role. 
In addition, Western blot studies of the apoptosis marker PARP/cleaved PARP 
were performed. Incubation time of 16 h and concentrations of 2-4 ?M of 1a and 
1-2 ?M of 1b were chosen in order to provide an optimal setting for apoptosis 
and PARP cleavage. Both compounds showed cleaved PARP bands from 
which follows that 1a and 1b are inducing apoptosis. 
 
 
 
Conclusions 43 
Finally, these results are leading to the conclusion that metal complexes with 
indoloquinoline ligands have a high potential for antitumor activity. Further 
studies are necessary to verify the main target of these compounds, in addition 
the cellular uptake of the complexes as well as drug-DNA interactions are points 
of interest.  
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Structure-Activity Relationships of Highly Cytotoxic Copper(II) Complexes with
Modified Indolo[3,2-c]quinoline Ligands
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A number of indolo[3,2-c]quinolines were synthesized and modified at the lactam unit to provide a peripheral binding
site able to accommodate metal ions. Potentially tridentate ligands HL1a-HL4a and HL1b-HL4b were reacted with
copper(II) chloride in isopropanol/methanol to give novel five-coordinate copper(II) complexes [Cu(HL1a-4a)Cl2] and
[Cu(HL1b-4b)Cl2]. In addition, a new complex [Cu(HL
5b)Cl2] and two previously reported compounds [Cu(HL
6a)Cl2]
and [Cu(HL6b)Cl2] with modified paullone ligandsHL
5b,HL6a, and HL6b, which can be regarded as close analogues of
indoloquinolines HL1b, HL4a, and HL4b, in which the pyridine ring was formally substituted by a seven-membered
azepine ring, were synthesized for comparison. The new ligands and copper(II) complexes were characterized by
1H and 13C NMR, IR and electronic absorption spectroscopy, ESI mass spectrometry, magnetic susceptibility
measurements in solution at 298 K ([Cu(HL1a)Cl2] and [Cu(HL
4b)Cl2]), and X-ray crystallography ([Cu(HL
3b)-
Cl2] 3 3DMF, [Cu(HL
4b)Cl2] 3 2.4DMF, HL
5b and [Cu(HL5b)Cl2] 3 0.5CH3OH). All complexes were tested for cytotoxicity
in the human cancer cell lines CH1 (ovarian carcinoma), A549 (non-small cell lung cancer), and SW480 (colon
carcinoma). The compounds are highly cytotoxic, with IC50 values ranging from nanomolar to very low micromolar
concentrations. Substitution of the seven-membered azepine ring in paullones by a pyridine ring resulted in a six- to
nine-fold increase of cytotoxicity in SW480 cells. Electron-releasing or electron-withdrawing substituents in position 8
of the indoloquinoline backbone do not exert any effect on cytotoxicity of copper(II) complexes, whereas copper(II)
compounds with Schiff bases obtained from 2-acetylpyridine and indoloquinoline hydrazines are 10 to 50 times more
cytotoxic than those with ligands prepared from 2-formylpyridine and indoloquinoline hydrazines.
Introduction
In recent years, metal complexes which are able to interfere
with cellular structures have attracted great interest as potential
anticancer drugs. Complexes with biologically active ligands
are particularly attractive, as they combine qualities of classic
non-targeted coordination compounds and organic ligands
with selectivity for cellular targets (e.g., enzymes).1-10 Indolo-
[3,2-d]benzazepines, also namedpaullones, have been reported
as potent inhibitors of intracellular proteins, for example,
cyclin-dependent kinases (CDKs), glycogen synthase kinase-3β
and mitochondrial malate dehydrogenase.11-13 Since the
original paullones do not possess suitable binding sites for
metal ions, novel derivatives able to coordinate to gallium(III),
ruthenium(II), osmium(II), and copper(II) have beendesigned
and synthesized.14-18 All complexes exhibit remarkable
cytotoxicity in vitro, whereby the complexes with copper(II),
the only physiologically relevantmetal ion used, showed IC50
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values in the low micromolar and high nanomolar con-
centration range.18 Furthermore, the effect of metal coordi-
nation on solubility in aqueous media and on the impact on
cell cycle progression have been reported as well.14-18
As an extension to this previous work, we were interested
in studying the effect of substitution of the folded seven-
membered azepine ring in indolo[3,2-d ]benzazepines by a flat
six-membered pyridine ring, prompting us to prepare the
corresponding indolo[3,2-c]quinolines. Quite recently, the first
ruthenium(II) and osmium(II) complexes with indolo[3,2-
c]quinolines have been reported.19 The modified indolo[3,2-
c]quinoline ligands as well as their ruthenium(II) and osmium-
(II) complexes were all more cytotoxic than the corresponding
modified paullone ligands and their complexes.19 Further-
more, the indoloquinolines and their complexes readily
intercalate into DNA as evidenced by 90% replacement of
methyl green in a competitive replacement assay.19 These
results are in accord with the previous suggestion of other
authors that DNA is a possible intracellular target of
indoloquinolines.20
The pharmacological relevance of indoloquinolines is also
demonstrated by the fact that isocryptolepine, a derivative of
indolo[3,2-c]quinoline, and the closely related cryptolepine,
a derivative of indolo[3,2-b]quinoline, could be isolated
from the roots of Cryptolepis sanguinolenta, an African
plant used in traditional medicine to fight malaria.21-23
Whereas cryptolepine was extensively studied for its
medicinal applicability, isocryptolepine and further indolo-
[3,2-c]quinolines were only explored by researchers to a
limited extent, although their antiproliferative activity in
vitro has been confirmed.24-29
Herein we report on the synthesis of the first copper(II)
complexes with tridentate modified indolo[3,2-c]quinoline
ligands (Scheme 1), related to the quite recently published
copper(II) complexes with indolo[3,2-d ]benzazepine-based
ligands.18 Todirectly compare the two classes of heterocycles,
one novel copper(II) complex with aN-(7,12-dihydroindolo-
[3,2-d ][1]benzazepin-6-yliden)-N0-(1-pyridin-2-yl-ethyliden)
azine ligand and two complexes reported previously have
been synthesized (Chart 1), and their cytotoxicity was com-
pared to those of indoloquinolines. Effects of the substitution
of the seven-membered azepine ring by the six-membered
Scheme 1. Synthesis of 1a-4ba and Numbering Schemes for Original and Modified Indoloquinolinesb
aReagents and conditions: (i) borane, 1.0M in THF, THF, Ar, rt, 48 h (B2, 61%), 24 h (B3, 96%), 72 h (B4, 83%); (ii) glacial AcOH, reflux, 4 h [(C1,
80%), (C2, 56%), (C3, 60%), (C4, 64%)]; (iii) POCl3, reflux, 24 h/NaOH, extraction with ethyl acetate [(D1, 97%), (D2, 72%), (D3, 86%), (D4, 90%)];
(iv)N2H4 3H2O, reflux, 24 h [(E1, 95%), (E2, 86%), (E3, 92%), (E4, 86%)]; (v) 2-formylpyridine, ethanol, reflux, 24 h [(HL
1a, 89%), (HL2a, 82%), (HL3a,
90%), (HL4a, 78%)] or 2-acetylpyridine, ethanol, reflux, 24 h [ (HL1b, 89%), (HL2b, 83%), (HL3b, 94%), (HL4b, 84%)]; (vi) CuCl2 3 2H2O, isopropanol,
reflux, 30 min [(1a, 82%), (1b, 90%), (2a, 86%), (2b, 94%), (3a, 83%), (3b, 86%), (4a, 85%), (4b, 91%)]. bUnderlined compounds have been
characterized by X-ray crystallography.
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pyridine ring and other structure-activity relationships are
discussed.
Experimental Section
Starting Materials. 2-Aminobenzonitrile (A1), 2-amino-
5-methylbenzonitrile (A2), borane tetrahydrofuran complex
solution, 2-aminobenzylamine (B1), isatin, glacial acetic acid,
phosphorus oxychloride, hydrazine hydrate, 2-formylpyridine,
2-acetylpyridine, copper(II) chloride dihydrate and dimethyl-
formamide were all purchased from Sigma-Aldrich and used
without further purification. 2-Amino-5-chlorobenzonitrile (A3)
and isopropanol (analytical reagent grade) were purchased from
Acros Organics. Tetrahydrofuran (THF, analytical reagent
grade) was purchased from Fisher Scientific and dried using
standard protocols. Ethanol (96%) and diethyl ether were
purchased from Brenntag and Donauchem, correspondingly.
2-Amino-5-bromobenzonitrile (A4) was synthesized according
to Roche et al.30 The substituted benzylamines (B2-B4), were
obtained by reduction of compoundsA2-A4with borane in dry
THF, according to the procedure reported by Giordani et al.31
The syntheses of compounds C1,32 D1,20 E1,33 HL1a, and
HL1b 34 were performed following the literature procedures.
7,12-Dihydroindolo[3,2-d ][1]benzazepine-6(5H)-thione (Chart 1)
was prepared following a published protocol.35 2-Acetylpyridine
hydrazone was obtained by reacting 2-acetylpyridine with excess
hydrazine hydrate as the reagent and solvent at room temperature
for 24 h.
General Procedure for the Synthesis of Substituted Benzyla-
mines (B2, B3). To a solution of substituted benzonitrile in dry
THF at 0 C under an argon atmosphere was slowly added
borane (1.0M inTHF).The reactionmixturewas stirred for 10min
at 0 Cand further 48h (B2), or 24h (B3) at room temperature.The
reaction mixture was cooled to 0 C and quenched by addition
of ethanol (96%). The resulting solution was saturated with
gaseous HCl. The precipitated dihydrochloride was filtered
off and then treated with an aqueous solution of ammonia.
The resulting suspension was extracted with ethyl acetate (3 
20 mL). The combined organic layers were dried over sodium
sulfate. Ethyl acetate was completely removed under reduced
pressure and the product further dried in vacuo.
2-Amino-5-methylbenzylamine (B2). 2-Amino-5-methylben-
zonitrile (0.95 g, 7.2 mmol), freshly dried THF (20 mL), borane
(1.0 M in THF, 9 mL), 48 h. Yield: 0.59 g, 61%. C8H12N2,
Mr=136.91 g/mol.
1HNMR (CDCl3, δH): 6.91 (d, 1H,
3J(HC3)=
7.9Hz, C4), 6.90 (s, 1H, C6), 6.63 (d, 1H, 3J(HC4)=7.3Hz, C3),
4.36 (bs, 2H, N(C2)), 3.88 (s, 2H, C7), 2.25 (s, 3H, C8), 1.41 (bs,
2H, N(C7)). 13C{1H} NMR (CDCl3, δC): 143.63 (C2), 129.70
(C6), 128.59 (C4), 127.21 (C1), 126.40 (C6), 115.99 (C3), 44.93
(C7), 20.39 (C8).
2-Amino-5-chlorobenzylamine (B3). 2-Amino-5-chlorobenzo-
nitrile (3.01 g, 19.76 mmol), freshly dried THF (50 mL), borane
(1.0 M in THF, 24 mL), 24 h. Yield: 2.93 g, 96%. C7H9ClN2,
Mr = 156.61 g/mol.
1H NMR (DMSO-d6, δH): 7.08 (s, 1H,
4J(HC4)=2.4 Hz, C6), 6.93 (d, 1H,
3J(HC3)=8.5 Hz,
4J(HC6)=
2.4 Hz, C4), 6.61 (d, 1H, 3J(HC4) = 8.0 Hz, C3), 5.21 (s, 2H,
N(C2)), 3.58 (s, 2H, C7), 1.80 (s, 2H, N(C7)). 13C{1H} NMR
(DMSO-d6, δC): 145.94 (C2), 129.09 (C1), 127.67 (C6), 126.87
(C4), 119.57 (C5), 116.17 (C3), 42.97 (C7).
General Procedure for the Synthesis of 8-Substituted 5,11-
Dihydroindolo[3,2-c]quinolin-6-ones.Amixture of isatin and the
respective benzylamine in glacial acetic acid was refluxed for 4 h
under argon atmosphere. After cooling to room temperature the
light-brown precipitate was filtered off, washed with acetic acid
(2  5 mL), water, and diethyl ether and dried in vacuo.
8-Methyl-5,11-dihydroindolo[3,2-c]quinolin-6-one (C2). Isatin
(0.58 g, 3.94 mmol), 2-amino-5-methylbenzylamine (0.56 g,
4.04 mmol), glacial acetic acid (10 mL). Yield: 0.54 g, 56%.
Anal. Calcd for C16H12N2O (Mr=248.28 g/mol) (%): C, 77.40;
H, 4.87; N, 11.28. Found: C, 77.19; H, 4.78; N, 11.12. 1H NMR
(DMSO-d6, δH): 12.41 (s, 1H, N11), 11.38 (s, 1H, N5), 8.16 (d,
1H, 3J(HC2)=7.9 Hz, C1), 8.01 (s, 1H, C7), 7.51-7.47 (m, 2H,
C3, C10), 7.44 (d, 1H, 3J(HC3) = 7.6 Hz, C2), 7.26 (dd, 1H,
3J(HC1)=7.6Hz,
3J(HC3)=7.6Hz, C2), 7.18 (d, 1H,
3J(HC10)=
8.2 Hz, C9), 2.47 (s, 3H, C8a). 13C{1H} NMR (DMSO-d6, δC):
160.35 (C6), 141.15 (C11a), 138.34 (C4a), 136.42 (C10a), 130.28
(C8), 129.48 (C3), 125.86 (C9), 125.09 (6b), 122.49 (C1), 121.89
(C2), 121.01 (C7), 116.44 (C4), 112.51 (C11b), 111.77 (C10),
106.57 (C6a), 21.70 (C8a).
8-Chloro-5,11-dihydroindolo[3,2-c]quinolin-6-one (C3). Isatin
(0.66 g, 4.50 mmol), 2-amino-5-chlorobenzylamine (0.80 g,
5.11 mmol), glacial acetic acid (10 mL). Yield: 0.72 g, 60%. Anal.
Calcd for C15H9ClN2O (Mr=268.70 g/mol) (%): C, 67.05; H,
3.38; N, 10.43. Found: C, 66.67; H, 3.14; N, 10.29. 1H NMR
(DMSO-d6, δH): 12.74 (s, 1H, N11), 11.51 (s, 1H, N5), 8.18 (d,
1H, 3J(HC2)=7.9Hz,C1), 8.14 (s, 1H,C7), 7.63 (d, 1H,
3J(HC9)=
8.5 Hz, C10), 7.53 (dd, 1H, 3J(HC2)=7.6 Hz,
3J(HC4)=7.6 Hz,
C3), 7.46 (d, 1H, 3J(HC3)=7.6 Hz, C4), 7.37 (d, 1H,
3J(HC10)=
8.5Hz,C9), 7.31 (dd, 1H, 3J(HC1)=7.6Hz,
3J(HC3)=7.6Hz,C2).
13C{1H} NMR (DMSO-d6, δC): 160.05 (C6), 142.32 (C11a),
138.65 (C4a), 136.69 (C10a), 130.13 (C3), 126.00 (C6b), 125.99
(C8), 124.36 (C9), 122.75 (C1), 122.16 (C2), 120.15 (C7), 116.65
(C4), 113.78 (C10), 112.17 (C11b), 106.40 (C6a).
8-Bromo-5,11-dihydroindolo[3,2-c]quinolin-6-one (C4). Isatin
(0.37 g, 2.51 mmol), 2-amino-5-bromobenzylamine (0.56 g,
2.76 mmol), glacial acetic acid (3.5 mL). Yield: 0.50 g, 64%. Anal.
Calcd for C15H9BrN2O (Mr=313.15 g/mol) (%): C, 57.53; H,
2.90; N, 8.95. Found: C, 57.22; H, 2.71; N, 8.62. 1H NMR
(DMSO-d6, δH): 12.75 (s, 1H, N11), 11.52 (s, 1H, N5), 8.29
(s, 1H, C7), 8.18 (d, 1H, 3J(HC2) = 7.9 Hz, C1), 7.59 (d, 1H,
3J(HC9) = 8.5 Hz, C10), 7.54 (dd, 1H,
3J(HC2) = 7.6 Hz,
3J(HC4)=7.6 Hz, C3), 7.50 (d, 1H,
3J(HC10)=8.5 Hz, C9), 7.48
(d, 1H, 3J(HC3)=7.6 Hz, C4), 7.31 (dd, 1H,
3J(HC1)=7.9 Hz,
3J(HC3)=7.6 Hz, C2).
13C{1H} NMR (DMSO-d6, δC): 160.04
(C6), 142.14 (C11a), 138.66 (C4a), 136.96 (C10a), 130.14 (C3),
126.92 (C9), 126.62 (C6b), 123.17 (C7), 122.76 (C1), 122.17
Chart 1. Starting Materials for the Synthesis of Complex 5b and
Numbering Scheme for Complexes 5b, 6a, and 6b with Paullone-Based
Tridentate Ligandsa
aThe underlined compound has been characterized by X-ray crystal-
lography. Compounds 6a and 6b were prepared as described recently.18
(30) Roche, D.; Prasad, K.; Repic, O.; Blacklock, T. J. Tetrahedron Lett.
2000, 41, 2083–2085.
(31) Giordani, A.; Mandelli, S.; Verpilio, I.; Zanzola, S.; Tarchino, F.;
Caselli, G.; Piepoli, T.; Mazzari, S.; Makovec, F.; Rovati, L. C. PCT Int.
Appl. WO 2008014822, 2008, 57 pp.
(32) Bergman, J.; Engqvist, R.; St

alhandske, C.; Wallberg, H. Tetrahedron
2003, 59, 1033–1048.
(33) Mulwad, V. V.; Lohar, M. V. Indian J. Chem. B 2003, 8, 1937–1942.
(34) Filak, L. K.; M€uhlgassner, G.; Roller, A.; Jakupec, M. A.; Galanski,
M.; Keppler, B. K.; Arion, V. B. Organometallics, submitted.
(35) Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. W.; Gussio, R.;
Sausvilee, E. A.; Meijer, L.; Kunick, C. J. Med. Chem. 1999, 42, 2909–2919.
Appendix 55 
 
Article Inorganic Chemistry, Vol. 49, No. 23, 2010 11087
(C2), 116.65 (C4), 114.23 (C10), 113.89 (C8), 112.14 (C11b),
106.27 (C6a).
General Procedure for the Synthesis of 8-Substituted 6-Chloro-
11H-indolo[3,2-c]quinolines.To8-substituted5,11-dihydroindolo-
[3,2-c]quinolin-6-one was added POCl3 as a reagent and solvent
under argon atmosphere. The reaction mixture was refluxed for
24 h. After cooling to room temperature the reaction mixture
was poured onto ice (200 mL) and slowly neutralized with solid
sodium hydroxide until a pH of 6-7 was reached. The resulting
aqueous suspensionwas extracted with ethyl acetate (5 200mL).
The combined organic layers were washed with 5% NaHCO3
aqueous solution (2 250 mL) and dried over Na2SO4. Ethyl
acetate was evaporated under reduced pressure to yield the
product as a beige solid, which was dried in vacuo.
6-Chloro-8-methyl-11H-indolo[3,2-c]quinoline (D2). C2 (0.51 g,
2.05 mmol), POCl3 (20 mL). Yield: 0.40 g, 72%. Anal. Calcd for
C16H11ClN2 3 0.25C4H8O2 (Mr=288.75 g/mol) (%): C, 70.71; H,
4.54; N, 9.70. Found: C, 70.85; H, 4.35; N, 9.85. 1H NMR
(DMSO-d6, δH): 12.99 (s, 1H, N11), 8.52 (d, 1H,
3J(HC2) =
8.2 Hz, C1), 8.23 (s, 1H, C7), 8.03 (d, 1H, 3J(HC3) = 8.2 Hz,
C4), 7.77 (dd, 1H, 3J(HC2)=8.2 Hz,
3J(HC4)=8.4 Hz, C3), 7.71
(dd, 1H, 3J(HC1)=8.1 Hz,
3J(HC3)=8.1 Hz, C2), 7.65 (d, 1H,
3J(HC9)=8.4 Hz, C10), 7.38 (d, 1H,
3J(HC10)=8.4 Hz, C9), 2.54
(s, 3H, C8a). 13C{1H} NMR (DMSO-d6, δC): 144.92 (C6), 144.76
(C4a), 142.46 (C11a), 137.54 (C10a), 130.70 (C6b), 129.56 (C3),
128.83 (C4), 127.96 (C9), 126.70 (C2), 122.64 (C1), 121.47 (C8),
121.41 (C7), 117.03 (C11b), 112.32 (C10), 111.62 (C6a), 21.81
(C8a). ESI-MS in methanol (positive): 267 [(D2)H]þ, 289
[(D2)Na]þ, 555 [(D2)2Na]
þ.
6,8-Dichloro-11H-indolo[3,2-c]quinoline (D3). C3 (0.72 g,
2.66 mmol), POCl3 (20 mL). Yield: 0.66 g, 86%. Anal. Calcd
for C15H8Cl2N2 (Mr=287.14 g/mol) (%): C, 62.74; H, 2.81; N,
9.76. Found: C, 62.40;H, 2.86; N, 9.51. 1HNMR (DMSO-d6, δH):
13.26 (s, 1H,N11), 8.51 (d, 1H, 3J(HC2)=7.9Hz, C1), 8.34 (s, 1H,
C7), 8.04 (d, 1H, 3J(HC3)=8.2 Hz, C4), 7.80 (dd, 1H,
3J(HC2)=
7.6 Hz, 3J(HC4)=7.9 Hz, C3), 7.77 (d, 1H,
3J(HC9)=8.5 Hz,
C10), 7.73 (dd, 1H, 3J(HC1)=7.9 Hz,
3J(HC3)=7.6 Hz, C2),
7.56 (d, 1H, 3J(HC10)=8.5 Hz, C9).
13C{1H} NMR (DMSO-
d6, δC): 145.03 (C4a), 144.71 (C6), 143.19 (C11a), 137.75
(C10a), 130.10 (C3), 128.91 (C4), 127.03 (C2), 126.47 (C9),
126.14 (C8), 122.76 (C1), 122.42 (C6b), 120.76 (C7), 116.89
(C11b), 114.28 (C10), 111.14 (C6a). ESI-MS in methanol
(positive): 287 [(D3)H]þ, 309 [(D3)Na]þ.
8-Bromo-6-chloro-11H-indolo[3,2-c]quinoline (D4). C4 (0.48 g,
1.55 mmol), POCl3 (20 mL). Yield: 0.05 g, 90%. C15H8BrClN2,
Mr = 331.59 g/mol.
1H NMR (DMSO-d6, δH): 13.28 (s, 1H,
N11), 8.52 (d, 1H, 3J(HC2)=8.2Hz,C1), 8.50 (s, 1H,C7), 8.05 (d,
1H, 3J(HC3) = 8.2 Hz, C4), 7.82 (dd, 1H,
3J(HC2) = 8.2 Hz,
3J(HC4)=8.2Hz, C3), 7.76 (dd, 1H,
3J(HC1)=7.9Hz,
3J(HC3)=
8.1 Hz, C2), 7.73 (d, 1H, 3J(HC9) = 8.7 Hz, C10), 7.68 (d, 1H,
3J(HC10)=8.7 Hz, C9).
13C{1H} NMR (DMSO-d6, δC): 145.04
(C4a), 144.70 (C6), 143.03 (C11a), 138.04 (C10a), 130.13 (C9),
129.07 (C3), 128.92 (C4), 127.07 (C2), 123.72 (C7), 123.03 (C6b),
122.79 (C1), 116.87 (C11b), 114.72 (C10), 113.98 (C8), 111.01
(C6a). ESI-MS in methanol (positive): 331 [(D4)H]þ, 353
[(D4)Na]þ.
General Procedure for the Synthesis of 8-Substituted 5,11-
Dihydroindolo[3,2-c]quinolin-6-ylhydrazines. To 8-substituted
6-chloro-11H-indolo[3,2-c]quinoline hydrazine hydrate as re-
agent and solvent was added and the reaction mixture heated at
115 C for 24 h under argon atmosphere. After cooling to room
temperature, the resulting beige precipitate was filtered off,
washed with water (210mL), ethyl acetate and dried in vacuo.
8-Methyl-5,11-dihydroindolo[3,2-c]quinolin-6-ylhydrazine (E2).
D2 (0.37 g, 1.4 mmol), hydrazine hydrate (10 mL). Yield: 0.31 g,
86%. Anal. Calcd for C16H14N4 3 0.1H2O (Mr = 264.11 g/mol):
C, 72.76; H, 5.42; N, 21.21. Found: C, 73.13; H, 5.17; N, 20.91.
1H NMR (DMSO-d6, δH): 12.35 (s, 1H, N11), 8.25 (d, 1H,
3J(HC2) = 7.3 Hz, C1), 8.19 (s, 1H, C7), 7.94 (s, 1H, N12),
7.74 (d, 1H, 3J(HC3)=7.0 Hz, C4), 7.56-7.50 (m, 2H, C3, C10),
7.36-7.28 (m, 1H, C2), 7.22 (d, 1H, 3J(HC10)=8.2Hz, C9), 4.68
(s, 2H, N13), 2.50 (s, 3H, C8a). ESI-MS in methanol (positive):
263 [(E2)H]þ.
8-Chloro-5,11-dihydroindolo[3,2-c]quinolin-6-ylhydrazine (E3).
D3 (0.64 g, 2.2 mmol), hydrazine hydrate (10 mL). Yield: 0.58 g,
92%. Anal. Calcd for C15H11ClN4 3 0.1C4H8O2 (Mr=291.54 g/
mol): C, 63.44; H, 4.08; N, 19.22. Found: C, 63.69; H, 3.74; N,
19.15. 1H NMR (DMSO-d6, δH): 12.66 (s, 1H, N11), 8.49 (bs,
1H, N12), 8.26 (d, 1H, 3J(HC2)=6.3 Hz, C1), 8.20 (s, 1H, C7),
7.75 (d, 1H, 3J(HC3)=6.3 Hz, C4), 7.63 (d, 1H,
3J(HC9)=8.2
Hz, C10), 7.60-7.54 (m, 1H, C3), 7.39 (d, 1H, 3J(HC10)= 7.9
Hz, C9), 7.37-7.31 (m, 1H, C2), 4.69 (s, 2H, N13). ESI-MS in
methanol (positive): 283 [(E3)H]þ.
8-Bromo-5,11-dihydroindolo[3,2-c]quinolin-6-ylhydrazine (E4).
D4 (1.0 g, 3.0 mmol), hydrazine hydrate (25 mL). Yield: 0.90 g,
86%. C15H11BrN4, Mr=327.18 g/mol.
1H NMR (DMSO-d6,
δH): 12.57 (bs, 1H, N11), 8.60 (bs, 1H), 8.36-8.16 (m, 2H),
7.79-7.70 (m, 1H), 7.64-7.45 (m, 3H), 7.41-7.24 (m, 1H), 4.58
(bs, 2H, N13). ESI-MS in methanol (positive): 327 [(E4)H]þ.
General Procedure for the Synthesis of Ligands (HL2a-4b). To
a suspension of 8-substituted 5,11-dihydroindolo[3,2-c]quinolin-
6-ylhydrazine in ethanol (96%, 10 mL) was added 2-formylpyr-
idine or 2-acetylpyridine at 50 C and the reaction mixture
heated at reflux for 24 h, and then cooled to room temperature.
The brightly yellow precipitate formedwas filtered off and dried
in vacuo.
N-(8-Methyl-5,11-dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-
(1-pyridin-2-yl-methylidene)azine (HL2a). E2 (0.10 g, 0.38 mmol),
2-formylpyridine (40.1 μL, 0.42 mmol). Yield: 0.12 g, 86%. Anal.
Calcd forC22H17N5 (Mr=351.40g/mol) (%):C, 75.19;H, 4.88;N,
19.93. Found: C, 74.97; H, 4.80; N, 19.60. 1H NMR (DMSO-d6,
δH): 12.44 (s, 1H, N11), 10.88 (s, 1H, N5), 8.62 (d, 1H,
3J(HC18)=
4.9 Hz, C17), 8.58 (d, 1H, 3J(HC19)=7.9 Hz, C20), 8.52 (s, 1H,
C14), 8.25 (s, 1H, C7), 8.13 (d, 1H, 3J(HC2) = 7.9 Hz, C1),
7.92-7.87 (m, 2H, C4, C19), 7.51 (d, 1H, 3J(HC9)=8.4 Hz, C10),
7.49 (dd, 1H, 3J(HC2)=7.7 Hz,
3J(HC4)=7.7 Hz, C3), 7.36 (dd,
1H, 3J(HC17) = 7.4 Hz,
3J(HC19) = 7.4 Hz, C18), 7.26 (dd, 1H,
3J(HC1)=7.6 Hz,
3J(HC3)=7.6 Hz, C2), 7.20 (d, 1H,
3J(HC10)=
8.4 Hz, C9), 2.50 (s, 3H, C8a). 13C{1H} NMR (DMSO-d6, δC):
155.52 (C15), 152.37 (C6), 150.85 (C14), 149.76 (C17), 139.05
(C11a), 137.92 (C4a), 136.97 (C10a), 136.57 (C19), 130.14 (C8),
129.53 (C3), 125.99 (C9), 124.33 (C6b), 123.71 (C18), 122.78 (C7),
122.32 (C1), 122.06 (C2), 121.42 (C20), 117.13 (C4), 113.67
(C11b), 111.69 (C10), 104.79 (C6a), 21.86 (C8a). The chemical
shift of methyl group protons 8a was determined by a HSQC
experiment, as theδ-value coincideswith that ofDMSO-d6 solvent
residual signal (see Supporting Information, Figure S1). ESI-MS
inmethanol (positive): 352 [(HL2a)H]þ, 374 [(HL2a)Na]þ.UV-vis
(isopropanol), λmax (ε, M
-1 cm-1): 230 (36900), 266 (27100), 330
(13750), 357 (13300), 410 (18500), 425 (18700).
N-(8-Methyl-5,11-dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-
(1-pyridin-2-yl-ethylidene)azine (HL2b). E2 (0.16 g, 0.59 mmol),
2-acetylpyridine (73 μL, 0.65 mmol). Yield: 0.18 g, 83%. Anal.
Calcd forC23H19N5 3H2O (Mr=383.45 g/mol) (%): C, 72.04;H,
5.52; N, 18.26. Found: C, 71.82; H, 5.31; N, 17.98. 1H NMR
(DMSO-d6, δH): 12.37 (s, 1H, N11), 10.66 (s, 1H, N5), 8.71 (d,
1H, 3J(HC19) = 8.0 Hz, C20), 8.61 (d, 1H,
3J(HC18)=4.9 Hz,
C17), 8.21 (s, 1H, C7), 8.10 (d, 1H, 3J(HC2)= 8.0 Hz, C1), 7.86
(d, 1H, 3J(HC3)= 7.6 Hz, C4), 7.83 (dd, 1H,
3J(HC18)= 7.4
Hz, 3J(HC20)= 7.4 Hz, C19), 7.50 (d, 1H,
3J(HC9)= 8.2 Hz,
C10), 7.45 (dd, 1H, 3J(HC2)=7.6 Hz,
3J(HC4)=7.6 Hz, C3),
7.35 (dd, 1H, 3J(HC19)=7.4Hz,
3J(HC17)=7.4Hz, C18), 7.25
(dd, 1H, 3J(HC1)=7.4 Hz,
3J(HC3)=7.6 Hz, C2), 7.20 (d, 1H,
3J(HC10) = 8.2 Hz, C9), 2.70 (s, 3H, C21), 2.49 (s, 3H, C8a).
13C{1H} NMR (DMSO-d6, δC): 157.28 (C15), 156.43 (C14),
150.67 (C6), 148.86 (C17), 138.72 (C11a), 137.99 (C4a), 136.98
(C10a), 136.24 (C19), 130.00 (C8), 129.40 (C3), 125.85 (C9),
124.46 (C6b), 123.45 (C18), 122.73 (C7), 122.24 (C1), 121.87
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(C2), 121.54 (C20), 117.20 (C4), 113.70 (C11b), 111.68 (C10),
105.59 (C6a), 22.03 (C8a), 13.55 (C21). The chemical shift of
methyl group protons 8a was determined by a HSQC experi-
ment, as the δ-value coincides with that of DMSO-d6 solvent
residual signal (see Supporting Information, Figure S2). ESI-MS
in methanol (positive): 366 [(HL2b)H]þ. UV-vis (isopropanol),
λmax (ε, M
-1 cm-1): 230 (39700), 267 (31100), 328 (16800), 354
(16550), 408 (19300).
N-(8-Chloro-5,11-dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-
(1-pyridin-2-yl-methylidene)azine (HL3a). E3 (0.24 g, 0.84 mmol),
2-formylpyridine (88 μL, 0.92 mmol). Yield: 0.28 g, 90%. Anal.
Calcd forC21H14ClN5 (Mr=371.82 g/mol) (%): C, 67.83;H, 3.80;
N, 18.84.Found:C, 67.53;H, 3.64;N, 18.44.1HNMR(DMSO-d6,
δH): 12.75 (s, 1H, N11), 10.94 (s, 1H, N5), 8.63 (d, 1H,
3J(HC18)=
4.9 Hz, C17), 8.58 (d, 1H, 3J(HC19)=7.9 Hz, C20), 8.52 (s, 1H,
C14), 8.39 (s, 1H, C7), 8.14 (d, 1H, 3J(HC2)=7.9 Hz, C1), 7.90 (d,
1H, 3J(HC3) = 8.2 Hz, C4), 7.89 (dd, 1H,
3J(HC18) = 7.7 Hz,
3J(HC20)=7.7Hz, C19), 7.64 (d, 1H,
3J(HC9)=8.7Hz, C10), 7.53
(dd, 1H, 3J(HC2)=7.9 Hz,
3J(HC4)=7.7 Hz, C3), 7.43-7.35 (m,
2H, C9, C18), 7.28 (dd, 1H, 3J(HC1)=7.6 Hz,
3J(HC3)=7.6 Hz,
C2). 13C{1H} NMR (DMSO-d6, δC): 155.35 (C15), 151.96 (C6),
151.49 (C14), 149.79 (C17), 140.19 (C11a), 138.30 (C4a), 137.20
(C10a), 136.60 (C19), 130.15 (C3), 125.82 (C8), 125.19 (C6b),
124.41 (C9), 123.87 (C18), 122.59 (C1), 122.24 (C2), 121.86 (C7),
121.52 (C20), 117.29 (C4), 113.66 (C10), 113.29 (C11b), 104.60
(C6a). ESI-MS in methanol (positive): 372 [(HL3a)H]þ. UV-vis
(isopropanol), λmax (ε, M
-1 cm-1): 233 (43350), 267 (32400), 304
(16400), 321 (13700), 363 (17400), 408 (19600).
N-(8-Chloro-5,11-dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-
(1-pyridin-2-yl-ethylidene)azine (HL3b). E3 (0.24 g, 0.85 mmol),
2-acetylpyridine (106 μL, 0.95 mmol). Yield: 0.31 g, 94%. Anal.
Calcd for C22H16ClN5 3H2O (Mr=403.86 g/mol) (%): C, 65.43;
H, 4.49; N, 17.34. Found: C, 65.46; H, 4.38; N, 17.07. 1HNMR
(DMSO-d6, δH): 12.69 (s, 1H, N11), 10.73 (s, 1H, N5), 8.71 (d,
1H, 3J(HC19)= 7.9 Hz, C20), 8.62 (d, 1H,
3J(HC18)= 4.9 Hz,
C17), 8.36 (s, 1H, C7), 8.11 (d, 1H, 3J(HC2)=7.3 Hz, C1), 7.88
(d, 1H, 3J(HC3)=7.9 Hz, C4), 7.89 (dd, 1H,
3J(HC18)=7.6 Hz,
3J(HC20)=7.6 Hz, C19), 7.63 (d, 1H,
3J(HC9)=8.5 Hz, C10),
7.50 (dd, 1H, 3J(HC2)=7.6 Hz,
3J(HC4)=7.9 Hz, C3), 7.41-
7.34 (m, 2H,C9,C18), 7.25 (dd, 1H, 3J(HC1)=7.6Hz,
3J(HC3)=
7.6 Hz, C2), 2.68 (s, 3H, C21). 13C{1H} NMR (DMSO-d6, δC):
157.12 (C6), 156.93 (C15), 150.24 (C14), 148.88 (C17), 139.89
(C11a), 138.37 (C4a), 137.20 (C10a), 136.28 (C19), 130.02 (C3),
125.73 (C8), 125.31 (C6b), 124.25 (C9), 123.60 (C18), 122.51
(C1), 122.05 (C2), 121.81 (C7), 121.62 (C20), 117.36 (C4), 113.64
(C10), 113.32 (C11b), 105.42 (C6a), 13.51 (C21). ESI-MS in
methanol (positive): 386 [(HL3b)H]þ. UV-vis (isopropanol),
λmax (ε, M
-1 cm-1): 231 (44200), 265 (34650), 309 (15900), 321
(15200), 360 (18650), 406 (19450).
N-(8-Bromo-5,11-dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-
(1-pyridin-2-yl-methylidene)azine (HL4a). E4 (0.26 g, 0.77 mmol),
2-formylpyridine (82 μL, 0.85 mmol). Yield: 0.25 g, 78%. Anal.
Calcd for C21H14BrN5 3 0.25H2O (Mr = 420.78 g/mol) (%): C,
59.94; H, 3.47; N, 16.64. Found: C, 59.98; H, 3.32; N, 16.44. 1H
NMR (DMSO-d6, δH): 12.77 (s, 1H,N11), 10.94 (s, 1H,N5), 8.64
(d, 1H, 3J(HC18)=4.7 Hz, C17), 8.58 (d, 1H,
3J(HC19)=7.7 Hz,
C20), 8.54 (s, 1H, C7), 8.51 (s, 1H, C14), 8.14 (d, 1H, 3J(HC2)=
7.4 Hz, C1), 7.94-7.85 (m, 2H, C4, C19), 7.59 (d, 1H, 3J(HC9)=
8.5 Hz, C10), 7.53 (dd, 1H, 3J(HC2)=7.7 Hz,
3J(HC4)=7.7 Hz,
C3), 7.50 (d, 1H, 3J(HC10)=8.5Hz,C9), 7.37 (dd, 1H,
3J(HC17)=
6.9 Hz, 3J(HC19)=7.1 Hz, C18), 7.28 (dd, 1H,
3J(HC1)=7.3 Hz,
3J(HC3)= 7.3 Hz, C2).
13C{1H} NMR (DMSO-d6, δC): 155.31
(C15), 151.95 (C6), 151.47 (C14), 149.80 (C17), 140.02 (C11a),
138.29 (C4a), 137.48 (C10a), 136.63 (C19), 130.15 (C3), 126.99
(C9), 125.77 (C6b), 124.87 (C7), 123.87 (C18), 122.60 (C1), 122.27
(C2), 121.53 (C20), 117.29 (C4), 114.09 (C10), 113.75 (C8), 113.24
(C11b), 104.43 (C6a). ESI-MS in methanol (positive): 416
[(HL4a)H]þ, 438 [(HL4a)Na]þ. UV-vis (isopropanol), λmax
(ε, M-1 cm-1): 233 (38700), 267 (29000), 303 (13350), 321 (12100),
361 (15150), 410 (18500).
N-(8-Bromo-5,11-dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-
(1-pyridin-2-yl-ethylidene)azine (HL4b). E4 (0.22 g, 0.52 mmol),
2-acetylpyridine (85 μL, 0.76 mmol). Yield: 0.19 g, 84%. Anal.
Calcd for C22H16BrN5 3H2O (Mr=448.32 g/mol) (%): C, 58.94;
H, 4.05; N, 15.62. Found: C, 58.81; H, 4.05; N, 15.38. 1H NMR
(DMSO-d6, δH): 12.70 (s, 1H, N11), 10.74 (s, 1H, N5), 8.72 (d,
1H, 3J(HC19)= 8.0 Hz, C20), 8.63 (d, 1H,
3J(HC18)= 4.7 Hz,
C17), 8.52 (s, 1H, C7), 8.12 (d, 1H, 3J(HC2)=8.0 Hz, C1), 7.89
(d, 1H, 3J(HC3)=8.0 Hz, C4), 7.85 (dd, 1H,
3J(HC18)=7.7 Hz,
3J(HC20)=7.7 Hz, C19), 7.59 (d, 1H,
3J(HC9)=8.5 Hz, C10),
7.54-7.49 (m, 2H, C3, C9), 7.37 (dd, 1H, 3J(HC17) = 7.3 Hz,
3J(HC19)=7.3Hz,C18), 7.26 (dd, 1H,
3J(HC1)=7.5Hz,
3J(HC3)=
7.5 Hz, C2), 2.68 (s, 3H, C21). 13C{1H} NMR (DMSO-d6, δC):
157.13 (C14), 157.00 (C15), 150.24 (C6), 148.89 (C17), 139.72
(C11a), 138.38 (C4a), 137.47 (C10a), 136.29 (C19), 130.05 (C3),
126.82 (C9), 125.94 (C6b), 124.91 (C7), 123.62 (C18), 122.54
(C1), 122.07 (C2), 121.64 (C20), 117.38 (C4), 114.10 (C10),
113.70 (C8), 113.29 (C11b), 105.30 (C6a), 13.48 (C21). ESI-
MS in methanol (positive): 430 [(HL4a)H]þ, 452 [(HL4a)Na]þ.
UV-vis (isopropanol), λmax (ε, M-1 cm-1): 231 (40400), 265
(32500), 310 (14500), 322 (13950), 360 (17450), 407 (18000).
Synthesis of Indolotriazoloquinoline L7.HL2a (19mg, 0.05mmol)
was dissolved in hot ethanol (96%, 15 mL). The solution was
filtered, concentrated to two-thirds of the initial volume and left to
stand at-20 C for 96 h. The yellowprecipitate formedwas filtered
off and dried in vacuo. Yield: 15mg, 80%. C22H15N5,Mr=349.39
g/mol. 1H NMR (DMSO-d6, δH): 12.67 (s, 1H, N11), 8.85 (d, 1H,
3J(HC18) = 4.7 Hz, C17), 8.49 (d, 1H,
3J(HC2) = 7.9 Hz, C1),
8.20-8.14 (m, 2H, C8, C19), 8.03 (d, 1H, 3J(HC19)=7.7Hz, C20),
7.71 (dd, 1H, 3J(HC17)=7.9Hz,
3J(HC19)=7.9Hz,C18), 7.65 (dd,
1H, 3J(HC1)=7.7Hz,
3J(HC3)=7.7Hz,C2), 7.62 (d, 1H,
3J(HC9)=
8.4 Hz, C10), 7.53 (d, 1H, 3J(HC3) = 8.4 Hz, C4), 7.46 (dd, 1H,
3J(HC2)=7.9 Hz,
3J(HC4)=7.9 Hz, C3), 7.31 (d, 1H,
3J(HC10)=
8.4 Hz, C9), 2.57 (s, 3H, C8a). 13C{1H} NMR (DMSO-d6, δC):
150.29 (C17), 149.59 (C15), 148.03 (C14), 147.61 (C6), 138.49
(C19), 137.09 (C10a), 134.55 (C11a), 130.64 (C8), 130.56 (C4a),
128.27 (C3), 126.88 (C9), 126.77 (C2), 126.44 (C20), 125.74 (C18),
123.69 (C1), 122.82 (C6b), 121.22 (C7), 118.92 (C4), 117.07 (C11b),
112.36 (C10), 101.57 (C6a), 21.73 (C8a).
General Procedure for the Synthesis of Complexes 1a-4b. To
a solution of the corresponding ligand in isopropanol, a solution
of CuCl2 3 2H2O in methanol (1 mL) was added at 60 C. The
reaction mixture, which turned dark-red, was heated at reflux
for further 15 min. The reaction mixture was cooled to room
temperature and the dark-red solid filtered off, washed with
isopropanol, and dried in vacuo.
N-(11H-Indolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-
methylidene)azine-dichlorido-copper(II) (1a). HL1a (0.10 g, 0.30
mmol), CuCl2 3 2H2O (0.06 g, 0.35 mmol), isopropanol (70 mL).
Yield: 0.115 g, 82%. Anal. Calcd for C21H15Cl2CuN5 3 0.5-
CH3OH (Mr=487.85 g/mol) (%): C, 52.93; H, 3.51; N, 14.36.
Found: C, 52.98; H, 3.25; N, 14.33. ESI-MS in methanol
(positive): 399 [CuL1a]þ, 435 [Cu(HL1a)Cl]þ, 736 [CuL1a(HL1a)]þ.
ATR-IR, selected bands, cm-1: 3090, 1581, 1527, 1224, 912, 741.
UV-vis (1% v/v DMSO/H2O), λmax (ε, M-1 cm-1): 238
(38100), 249 (34600), 257 (33400), 298 (18900), 319 (17500),
333 (15100), 461 (15000).
N-(11H-Indolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-
ethylidene)azine-dichlorido-copper(II) (1b).HL1b (0.10g, 0.28mmol),
CuCl2 3 2H2O (0.06 g, 0.35 mmol), isopropanol (70 mL). Yield:
0.125 g, 90%. Anal. Calcd for C22H17Cl2CuN5 (Mr=485.86 g/
mol) (%): C, 54.39; H, 3.53; N, 14.41. Found: C, 54.16; H,
3.42; N, 14.17. ESI-MS in methanol (positive): 413 [CuL1b]þ,
449 [Cu(HL1b)Cl]þ. ATR-IR, selected bands, cm-1: 3029,
1584, 1533, 1205, 750. UV-vis (1% v/v DMSO/H2O), λmax
(ε, M-1 cm-1): 237 (41450), 256 (33850), 299 (19850), 318
(19300), 333 (16900), 453 (17200).
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N-(8-Methyl-11H-indolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyri-
din-2-yl-methylidene)azine-dichlorido-copper(II) (2a). HL2a (0.02 g,
0.06mmol),CuCl2 3 2H2O(0.01g,0.07mmol), isopropanol (20mL).
Yield: 0.026 g, 86%. Anal. Calcd for C22H17Cl2CuN5 3 0.5H2O
(Mr=494.86 g/mol) (%): C, 53.40; H, 3.67; N, 14.15. Found: C,
53.79; H, 3.53; N, 13.90. ESI-MS in methanol (positive): 413
[CuL2a]þ, 449 [Cu(HL2a)Cl]þ. ATR-IR, selected bands, cm-1:
3214, 1585, 1536, 1230, 756. UV-vis (1% v/v DMSO/H2O), λmax
(ε, M-1 cm-1): 237 (39000), 253 (35300), 302 (18300), 323 (17900),
336 (16100), 462 (15250).
N-(8-Methyl-11H-indolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-
2-yl-ethylidene)azine-dichlorido-copper(II) (2b). HL2b (0.06 g,
0.15 mmol), CuCl2 3 2H2O (0.03 g, 0.18 mmol), isopropanol
(70 mL). Yield: 0.052 g, 94%. Anal. Calcd for C23H19Cl2Cu-
N5 3 0.5H2O (Mr = 508.89 g/mol) (%): C, 54.28; H, 3.96; N,
13.76. Found: C, 54.23; H, 3.75; N, 13.43. ESI-MS in methanol
(positive): 427 [CuL2b]þ, 463 [Cu(HL2b)Cl]þ. ATR-IR, selected
bands, cm-1: 3141, 1585, 1523, 1188, 768. UV-vis (1% v/v
DMSO/H2O), λmax (ε, M
-1 cm-1): 237 (42000), 255 (35500), 300
(19700), 320 (19600), 334 (17500), 454 (16300).
N-(8-Chloro-11H-indolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-
2-yl-methylidene)azine-dichlorido-copper(II) (3a). HL3a (0.07 g,
0.19 mmol), CuCl2 3 2H2O (0.04 g, 0.22 mmol), isopropanol
(70 mL). Yield: 0.077 g, 83%. Anal. Calcd for C21H14Cl3-
CuN5 3 0.2C3H8O (Mr = 518.29 g/mol) (%): C, 50.05; H, 3.03;
N, 13.51. Found: C, 49.71; H, 2.76; N, 13.16. ESI-MS in
methanol (positive): 372 [(HL3a)H]þ, 433 [CuL3a]þ, 469 [Cu-
(HL3a)Cl]þ, 804 [CuL3a(HL3a)]þ. ATR-IR, selected bands,
cm-1: 3271, 3203, 3045, 1583, 1230, 755. UV-vis (1% v/v
DMSO/H2O), λmax (ε, M
-1 cm-1): 232 (52300), 260 (31200),
299 (17150), 320 (15200), 336 (13900), 465 (9700).
N-(8-Chloro-11H-indolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-
2-yl-ethylidene)azine-dichlorido-copper(II) (3b). HL3b (0.07 g,
0.18 mmol), CuCl2 3 2H2O (0.04 g, 0.21 mmol), isopropanol
(70 mL). Yield: 0.078 g, 86%. Anal. Calcd for C22H16Cl3-
CuN5 3 0.2C3H8O (Mr=532.32 g/mol) (%): C, 50.99; H, 3.33;
N, 13.16. Found: C, 50.65; H, 3.08; N, 12.93. ESI-MS in
methanol (positive): 447 [CuL3b]þ, 483 [Cu(HL3b)Cl]þ, 832
[CuL3b(HL3b)]þ. ATR-IR, selected bands, cm-1: 3144, 2659,
1579, 1527, 1210, 933, 763. UV-vis (1% v/v DMSO/H2O),
λmax (ε, M
-1 cm-1): 235 (54800), 260 (33000), 303 (20000), 318
(19400), 333 (17700), 453 (15800). Single crystals of the com-
position 3b 3 3DMF, suitable for an X-ray diffraction study,
were obtained by slow diffusion of diethyl ether into a solution
of the complex in DMF.
N-(8-Bromo-11H-indolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-
2-yl-methylidene)azine-dichlorido-copper(II) (4a). HL4a (0.09 g,
0.22 mmol), CuCl2 3 2H2O (0.04 g, 0.26 mmol), isopropanol
(80 mL). Yield: 0.078 g, 85%. Anal. Calcd for C21H14BrCl2-
CuN5 3 0.25H2O (Mr=555.23 g/mol) (%): C, 45.42; H, 2.63; N,
12.61. Found: C, 45.66; H, 2.52; N, 12.21. ESI-MS in methanol
(positive): 477 [CuL4a]þ, 513 [Cu(HL4a)Cl]þ, 892 [CuL4a-
(HL4a)]þ. ATR-IR, selected bands, cm-1: 3129, 1580, 1528,
1368, 1220, 761. UV-vis (1% v/v DMSO/H2O), λmax (ε, M-1
cm-1): 238 (47300), 303 (17500), 320 (16800), 336 (15600), 461
(14100).
N-(8-Bromo-11H-indolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-
2-yl-ethylidene)azine-dichlorido-copper(II) (4b). HL4b (0.09 g,
0.21 mmol), CuCl2 3 2H2O (0.05 g, 0.28 mmol), isopropanol
(80 mL). Yield: 0.082 g, 91%. Anal. Calcd for C22H16BrCl2-
CuN5 (Mr = 564.75 g/mol) (%): C, 46.79; H, 2.86; N, 12.40.
Found: C, 46.96; H, 2.81; N, 12.11. ESI-MS in methanol
(positive): 491 [CuL4b]þ, 527 [Cu(HL4b)Cl]þ. ATR-IR, selected
bands, cm-1: 3140, 2831, 1575, 1526, 1212, 757. UV-vis (1% v/v
DMSO/H2O), λmax (ε, M
-1 cm-1): 237 (47700), 304 (17650), 319
(16850), 333 (15600), 456 (13800). Single crystals of X-ray
diffraction quality of the composition 4b 3 2.4DMF were ob-
tained by slow diffusion of diethyl ether into a solution of the
complex in DMF.
N-(7,12-Dihydroindolo[3,2-d][1]benzazepin-6-yliden)-N0-
(1-pyridin-2-yl-ethylidene)azine-dichlorido-copper(II) (5b). A mix-
ture of 7,12-dihydroindolo[3,2-d][1]benzazepine-6(5H)-thione (0.31
g, 1.2 mmol) and 2-acetylpyridine hydrazone (0.20 g, 1.5 mmol) in
dry ethanol (25mL)was refluxed for 96 h. The yellowprecipitate
formed was filtered off, washed with ethanol, and dried in vacuo.
The 1HNMRspectrumconfirmed the formationof the ligand and
the presence of minor amounts of side products. The mother
liquor allowed to stand at -20 C for 2 days generated X-ray
diffraction quality single crystals ofHL5b. To a refluxed solution
of the crude ligand (0.11 g) in methanol (14 mL) was added
copper(II) chloride dihydrate (0.052 g) in methanol (1 mL). The
resulting brown solutionwas filtered hot and allowed to stand at
room temperature for 48 h. The crystals formedwere filtered off,
washed with cold methanol, and dried in vacuo. Yield: 0.07 g.
Anal. Calcd for C23H19Cl2CuN5 3 0.5CH3OH (Mr = 515.90 g/
mol) (%): C, 54.71; H, 4.10; N, 13.57. Found: C, 54.46; H, 3.90;
N, 13.33. ESI-MS inmethanol (positive): 427 [CuL5b]þ. UV-vis
(1% v/v DMSO/H2O), λmax (ε, M
-1 cm-1): 239 (31400),
299 (20400), 422 (8800). Single crystals of the composition
5b 3 0.5CH3OH suitable for an X-ray diffraction study were
picked directly from the reaction vessel.
Physical Measurements. 1H and 13C, NOE difference and
two-dimensional 1H-1H COSY, 1H-1H TOCSY, 1H-13C HSQC
and 1H-13C HMBC NMR spectra were recorded on a Bruker
Avance III spectrometer (Ultrashield Magnet) in DMSO-d6 or
CDCl3 at 25 C using standard pulse programs at 500.10 (1H)
and 125.76 (13C) MHz. 1H and 13C chemical shifts are quoted
relative to the residual solvent signals. Elemental analyses were
carried out at the Microanalytical Service of the Faculty of
Chemistry of the University of Vienna. Electrospray ionization
mass spectrometry was carried out using a Bruker Esquire 3000
instrument (Bruker Daltonic, Bremen, Germany) on samples
dissolved in methanol. UV-vis spectra were recorded on a
Perkin-Elmer Lambda 650 spectrophotometer, using samples
dissolved in isopropanol for HL1a-4b and 1% (v/v) DMSO-
water mixture for 1a-5b. The aqueous solution behavior of
complexes 1a, 1b, 4a, 4b, and 5b was monitored on a Perkin-
Elmer 12 UV-vis spectrophotometer in a 1% (v/v) DMSO/
water mixture at room temperature over 24 h. IR spectra were
measured with a Bruker Vertex 70 Fourier transform IR spec-
trometer by means of the attenuated total reflection (ATR)
technique. Magnetic susceptibility measurements were conducted
in solution on a Bruker Avance III spectrometer (Ultrashield
Magnet) in DMSO-d6 at 298 K using the Evans method.
41-43
The μeff calculated for a 0.018 M Cu(acac)2 solution in DMSO-d6
was 1.75 μB.
Crystallographic Structure Determination. X-ray diffraction
measurements were performed on a Bruker X8 APEXII CCD
diffractometer. Single crystals were positioned at 35 mm from
the detector, and 1241, 2557, 1226, and 2619 frames were
measured, each for 60, 80, 90, and 20 s over 1 scan width for
3b 3 3DMF, 4b 3 2.4DMF, HL
5b, and 5b 3 0.5CH3OH, correspond-
ingly.Thedatawereprocessedusing theSAINTsoftware.36Crystal
data, data collection parameters, and structure refinement details
are given in Table 1. The structures were solved by direct methods
and refined by full-matrix least-squares techniques. Non-H atoms
(36) SAINT-Plus, version 7.06a, and APEX2; Bruker-Nonius AXS Inc.:
Madison, WI, 2004.
(37) Sheldrick, G. M. SHELXS-97, Program for Crystal Structure Solu-
tion; University of G€ottingen: G€ottingen, Germany, 1997.
(38) Sheldrick, G. M. SHELXL-97, Program for Crystal Structure Re-
finement; University of G€ottingen: G€ottingen, Germany, 1997.
(39) Johnson, G. K. Report ORNL-5138; OAK Ridge National Labora-
tory: Oak Ridge, TN, 1976.
(40) Kunick, C. Liebigs Ann. Chem. 1993, 1141–1143.
(41) Evans, D. F. J. Chem. Soc. 1959, 2003–2005.
(42) Sur, S. K. Magn. Res. 1989, 82, 169–173.
(43) Ginzinger, W.; Arion, V. B.; Giester, G.; Galanski, M.; Keppler,
B. K. Cent. Eur. J. Chem. 2008, 6, 340–346.
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were refined with anisotropic displacement parameters with excep-
tion of those of co-crystallized solvent molecules in 3b 3 3DMF,
4b 3 2.4DMF, and 5 3 0.5CH3OH. H atoms were inserted in calcu-
lated positions and refined with a riding model. The disorder of
solvent molecules in 3b 3 3DMF was resolved with constrained
isotropic displacement parameters and restrained bond distances
using SADI instructions of SHELX97. The following software
programs were used: structure solution, SHELXS-97;37 refine-
ment, SHELXL-97;38 molecular diagrams, ORTEP;39 computer,
Pentium IV.
Cell Lines and Cell Culture Conditions. For cytotoxicity
determination, three different human cancer cell lines were used:
A549 (non-small cell lung cancer) and SW480 (colon carcinoma)
(both kindly provided by Brigitte Marian, Institute of Cancer
Research,DepartmentofMedicine I,MedicalUniversityVienna,
Austria) as well as CH1 (ovarian carcinoma) (kindly provided
by Lloyd R. Kelland, CRC Centre for Cancer Therapeutics,
Institute of Cancer Research, Sutton, U.K.). Cells were grown
as adherent monolayer cultures in 75 cm2 culture flasks
(Iwaki/Asahi Technoglass) in Minimal Essential Medium
supplemented with 10% heat-inactivated fetal bovine serum,
1 mM sodium pyruvate, 1% non essential amino acids (100)
and 2mML-glutamine but without antibiotics at 37 Cunder a
moist atmosphere containing 5% CO2 and 95% air. All cell
culture media and reagents were purchased from Sigma-Al-
drich Austria.
Cytotoxicity Assay. Cytotoxicity was determined by the
colorimetric MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide). For this assay, cells were
harvested by trypsinization and seeded into 96-well plates in
volumes of 100 μL/well. Depending on the cell line, different
cell densities were used to ensure exponential growth of the
untreated controls during the experiment: 1.5  103 cells/well
(CH1), 2.5 103 cells/well (SW480), 4.0 103 cells/well (A549).
In the first 24 h the cells were allowed to settle and resume
exponential growth. Then the test compounds were dissolved
in DMSO, mixed with medium to a maximum DMSO concen-
tration of 0.5% v/v, serially diluted and added to the plates in
volumes of 100 μL/well. After continuous exposure for 96 h (in
the incubator at 37 C and under 5% CO2), the medium was
replaced by 100 μL/well RPMI 1640 medium (supplemented
with 10% heat-inactivated fetal bovine serum and 2 mM
L-glutamine) and 20 μL/well MTT solution (MTT reagent in
phosphate-buffered saline, 5mg/mL), andplateswere incubated
for further 4 h. Then the medium/MTT mixture was removed
and the formed formazan product was dissolved in DMSO
(150 μL/well). Optical densities at 550 nm (and at a reference
wavelength of 690 nm) were measured with a microplate reader
(Tecan SpectraClassic). The quantity of vital cells was expressed
as a percentage of untreated controls, and 50% inhibitory con-
centrations (IC50) were calculated from the concentration-
effect curves by interpolation. Every test was repeated in at
least three independent experiments, each consisting of three
replicates per concentration level.
Results and Discussion
Syntheses of Ligands and Copper(II) Complexes. The
syntheses of modified indoloquinoline ligands and their
copper(II) complexes were performed as shown in
Scheme 1. Efforts by us were focused on the synthesis of
potentially tridentate ligands, taking into account our
recent experience with bi- and tridentate paullone ligands
and their copper(II) complexes. The copper(II) com-
plexes with bidentate paullones were found to dissociate
easily in an aqueous DMSO solution, while those of
tridentate paullones remained intact over 20 h.18
The 8-substituted 5,11-dihydroindolo[3,2-c]quinolin-
6-ones (C1-C4) were synthesized from isatin and the
corresponding benzylamines B1-B4 via the mechanism
described by Bergman et al.32 in moderate to good yields
(56-80%). It should be noted that the use of dihy-
drochlorides of B2-B4 as starting materials leads in each
case to the formation of an unidentified side product, which
can not be separated from the desired indoloquinoline.
Reaction ofC1-C4with POCl3 provided the 8-substituted
6-chloro-11H-indolo[3,2-c]quinolines (D135-D4) in good
toexcellent yields (72-97%).Treatmentof these compounds
with hydrazine hydrate yielded the hydrazine derivatives
E1-E4 in very good yields (86-92%).
The potentially tridentate Schiff bases HL1a-HL4b
were obtained by condensation reaction of the hydrazines
(E1-E4) with 2-formylpyridine (HL1a, HL2a, HL3a, and
HL4a) and 2-acetylpyridine (HL1b, HL2b, HL3b, HL4b),
respectively, in good to excellent yields.
Attempts to recrystallize HL2a from ethanol (96%) in
the presence of air oxygen resulted in formation of
Table 1. Crystal Data and Details of Data Collection for 3b 3 3DMF, 4b 3 2.4DMF, HL
5b, and 5b 3 0.5CH3OH
3b 3 3DMF 4b 3 2.4DMF HL
5b 5b 3 0.5CH3OH
empirical formula C31H37Cl3CuN8O3 C29.2H32.8BrCl2CuN7.4O2.4 C23H19N5 C23.5H21Cl2CuN5O0.5
Fw 739.58 740.18 365.43 515.89
space group P21/c P21/c P21/c P21/c
a [A˚] 17.5197(16) 17.439(2) 10.6889(7) 12.6541(4)
b [A˚] 14.2545(12) 14.3150(17) 13.6296(11) 13.9929(5)
c [A˚] 14.4463(11) 14.5007(18) 12.8100(9) 13.3138(4)
R [deg]
β [deg] 113.551(4) 113.292(5) 107.747(4) 107.041(2)
γ [deg]
V [A˚3] 3307.2(5) 3324.9(7) 1777.4(2) 2253.94(13)
Z 4 4 4 4
λ [A˚] 0.71073 0.71073 0.71073 0.71073
Fcalcd [g cm-3] 1.485 1.479 1.366 1.520
crystal size [mm3] 0.25  0.25  0.01 0.40  0.15  0.01 0.14  0.09  0.02 0.20  0.12  0.07
T [K] 100(2) 100(2) 100(2) 100(2)
μ [mm-1] 0.949 2.059 0.084 1.230
R1
a 0.0758 0.0865 0.0572 0.0327
wR2
b 0.2069 0.2404 0.1308 0.0990
GOFc 1.017 1.092 0.931 1.024
a R1=
P
||Fo|- |Fc||/
P
|Fo|.
b wR2={
P
w(Fo
2-Fc2)2/
P
w(Fo
2)2}1/2. cGOF={
P
[w(Fo
2-Fc2)2]/(n- p)}1/2, where n is the number of reflections and
p is the total number of parameters refined.
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indolotriazoloquinoline L7 (Chart 2). A similar transfor-
mation was discovered for HL1a coordinated to copper-
(II). Crystallization of [Cu(HL1a)Cl2] (1a) fromDMSO at
room temperature over 3 weeks afforded a new complex
of the composition [Cu(L8)2Cl2] (Chart 2). The structure
of this compound was established by X-ray diffraction
(Supporting Information, Figure S4), although the col-
lected data set was generally rather poor.
Cyclization to a triazole ring with formation of chelating
ligandsL7 andL8 presumably occurs via nucleophilic attack
by a secondary amino group =N5H at the imino carbon
atomC14 of the neighboringSchiff base formingCdNbond
inHL2a andHL1a, respectively, accompanied by 2 electron
oxidation coupled with a loss of two protons. It should be
also noted that the synthesis of some indolotriazolobenz-
azepines, which, however, are not suitable for chelatingmetal
ions, is well-documented in the literature.40 In contrast, we
did not observe cyclization with triazole ring formation in
the case of HL6a (Chart 2), indicating its lower reactivity
compared to related indoloquinolines.
Complexes 1a-4b were obtained in good to excellent
yields (82-94%), as shown in Scheme 1, by reacting the
corresponding ligands HL1a-4b in hot isopropanol with
copper(II) chloride dihydrate in methanol. The new com-
plex 5b and previously reported complexes 6a and 6b
were prepared analogously starting fromHL5b, HL6a, and
HL6b, and copper(II) chloride dihydrate inmethanol.18 The
modified paullone HL5b resulted from reaction of 7,12-
dihydroindolo[3,2-d][1]benzazepine-6(5H)-thione with 2-
acetylpyrdine hydrazone in dry boiling ethanol. The syn-
thesis of HL6a and HL6b was realized in two steps. First,
9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepine-6(5H)-
thione was reacted with hydrazine hydrate in dry ethanol,
yielding 9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-
6-ylhydrazine. This species was further condensed with
2-formylpyridine or 2-acetylpyridine, affordingHL6a and
HL6b, correspondingly.
Characterization of Ligands and Copper(II)Complexes.
Analytical data of the ligands and complexes are in agree-
ment with their formulations. The 1H and 13C NMR
spectral data of the ligands along with their assignments
are given in the Experimental Section. All ligands adopt a
configuration with an exocyclic C6dN12 double bond,
which could be confirmed by the presence of a proton at
N5 in the 1HNMR spectra and the chemical shifts of C6 in
the 13C NMR spectra.
Formation of copper(II) complexes was confirmed
by ESI mass spectrometry and magnetic susceptibility
measurements in solution. The spectra of complexes in
methanol showed peaks with m/z 399 (1a), 413 (1b), 413
(2a), 427 (2b), 433 (3a), 447 (3b), 477 (4a), 491 (4b) and 427
(5), which were attributed to [CuL]þ. In addition peaks
with m/z 435 (1a), 449 (1b), 449 (2a), 463 (2b), 469 (3a),
483 (3b), 513 (4a), and 527 (4b) were assigned to
[Cu(HL)Cl]þ. In some cases, peaks with high m/z values
of 736 (1a), 804 (3a), 832 (3b), and 892 (4a) were attrib-
uted to the formation of [CuL(HL)]þ ions in the mass
spectrometer.
Magnetic susceptibility measurements were carried out
in DMSO-d6 at 298 K exemplarily for complexes 1a and
4b using the Evans method.41,42 The calculated effective
magneticmoments of 1.76 and 1.75 μB, respectively, are in
accord with the d9 electronic configuration of copper(II)
with S=1/2.
UV-vis spectra of complexes 4b, 6b and their corre-
sponding ligands HL4b and HL6b in methanol are shown
in Figure 1. The spectrum of the heteroaromatic indolo-
quinoline-based ligandHL4b differs strongly from that of
the paullone ligandHL6b, in which the extended π system
is disrupted by methylene group carbon atom C7, and as
a result the ligand as a whole is non-planar. The light
absorption by HL4b is extended to the visible region,
with strong bands between 360 and 430 nm.
Coordination of ligands HL4b and HL6b to copper(II)
via the pyridine nitrogen atom, the hydrazine nitrogen
and the pyridine ring nitrogen atom or azepine nitrogen
atom, correspondingly, alters significantly the conjugated
π systems in both ligands, resulting in significantly dif-
ferent electronic absorption spectra. The orange solu-
tion of 4b and the yellow solution of 6b show signifi-
cant absorption in the visible region, namely, a broad
charge-transfer bandwith amaximum at 490 and 420 nm,
respectively.
Crystal Structures.Themolecular structures of copper-
(II) complexes 3b and 4b are shown in Figure 2. Selected
bond distances (A˚) and bond angles (deg) are given in the
legend to the figure. Both complexes (3b and 4b) crystal-
lized in the monoclinic space group P21/c with 3 and
2.4 molecules of dimethylformamide, correspondingly, in
Chart 2. Structures of the Ligand L7 and Copper(II) Complex
[Cu(L8)2Cl2] with a Relevant Atom Numbering Scheme
Figure 1. UV-vis spectra of (a) HL4b (blue) and 4b (red), compared
with (b)HL6b (blue) and 6b in methanol.
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the asymmetric unit. The molecules 3b partake in inter-
molecular hydrogen bonding interactions of the type
N11-H 3 3 3Cl1
i [N11 3 3 3Cl1
i 3.180 A˚], where i denotes a
symmetry code -x, y þ 0.5, -z þ 0.5 for generating
equivalent atom positions. In addition, a hydrogen bond
between the molecule of 3b and one of the neighboring
dimethylformamidemoleculesN12-H 3 3 3O1
i [N12 3 3 3O1
i
2.760 A˚] is evident in the crystal structure (Supporting
Information, Figure S3). The pattern of hydrogen bond-
ing interactions in the crystal structure of 4b 3 2.4DMF
is similar.
HL3b and HL4b act as neutral tridentate ligands in 3b
and 4b, respectively, coordinating to copper(II) via the
quinoline nitrogen atomN5 [Cu-N5=2.027(5) (3b) and
2.021(8) A˚ (4b)], the hydrazine group nitrogen atom N13
[Cu-N13= 1.974(6) (3b) and 1.988(9) A˚ (4b)], and the
pyridine ring nitrogen atom N16 [Cu-N16 = 2.023(5)
(3b) and 2.019(8) A˚ (4b)]. In contrast to paullone ligands,
which have a folded conformation both in the metal-free
and in the coordinated forms, the indoloquinolinesHL3b
andHL4b in 3b and 4b are essentially planar. The copper-
(II) center is five-coordinate, the remaining two coordi-
nating sites being occupied by two chlorido ligands. The
τ descriptor for 3b and 4b, expressed as the difference
between the angles N5-Cu-N16 and N13-Cu-Cl2
[157.7(2) and 133.86(16) (3b), and 158.5(4) and 134.2(2)
(4b)] divided by 60, gives the same value for both com-
plexes (0.40), which is between that for a trigonal bipyramid
(1) and that for a squarepyramid (0), and close to 0.52 found
in [Ga(L6b)Cl2].
43 Furthermore, the interatomic bond dis-
tance Cu-Cl2 is significantly longer in complexes 3b [Cu-
Cl2=2.3045(19) A˚] and 4b [Cu-Cl2 = 2.309(3) A˚] with
indoloquinoline ligands than in complexes 5b [Cu-Cl2 =
2.2461(5) A˚] and [Cu(HL6a)Cl2]
18 [Cu-Cl2=2.2411(8) A˚]
with paullone ligands.
The results of X-ray diffraction studies of the ligand
HL5b and complex 5b 3 0.5CH3OH are shown in Figure 3,
and selected bond lengths and bond angles are given in the
caption. Both the ligand and the complex crystallized in
the monoclinic space group P21/c.
Formation of a centrosymmetric dimer is due to a
bifurcated hydrogen bonding interaction between N12 as
a proton donor and atoms N17i and N14i as proton
acceptors [N12-H 0.880, H 3 3 3N17
i 2.079, N12 3 3 3N17
i
2.881 A˚, N12-H 3 3 3N17
i 151.1; H 3 3 3N14
i 2.633,
N12 3 3 3N14
i 3.356 A˚, N12-H 3 3 3N14
i 151.1]; i denotes a
symmetry code -x þ 1, -y, -z þ 2 for generating equiv-
alent atom positions (Supporting Information, Figure S5).
In addition, a hydrogen bondbetweenN5andN12i [N5-H
0.880,H 3 3 3N12
i 2.528,N5 3 3 3N12
i 3.335 A˚,N5-H 3 3 3N12
i
152.78] is evident in the crystal structure of HL5b.
The distribution of electron density over the fragment
N5-C6-N13 [N5-C6 1.359(3), C6-N13 1.329(3) A˚] in-
dicates the presence of an exocyclic amidine double bond.
Asexpected, the conformationof themetal-free ligandHL5b
is very similar to that of the 9-bromo-derivative.44 The
indolobenzazepine backbone in bothHL5b and 5b mainly
consists of sp2-hybridized carbon and nitrogen atoms. The
only exception is the methylene group carbon atom in the
seven-membered azepine ring, which is sp3-hybridized. This
atom disrupts the conjugation of the π system, and as a
result the ligand as a whole is non-planar.
Intermolecular hydrogen bonding interaction between
molecules of 5b, namely, N12-H 3 3 3Cl2
i [N12-H 0.880,
H 3 3 3Cl2
i 2.612, N12 3 3 3Cl2
i 3.338 A˚, N12-H 3 3 3Cl2
i
140.56], are responsible for their association in a dimer
(i denotes the symmetry code -x þ 1, -y þ 2, -z þ 1)
(Supporting Information,FigureS6).An interdimerichydro-
gen bond N13-H 3 3 3Cl1
ii (ii -x þ 2, y - 0.5, -z þ 1.5)
Figure 2. ORTEP plot of the molecules of 3b (left) and 4b (right) with thermal ellipsoids drawn at the 50% probability level. Selected bond distances
(A˚) andbondangles (deg) in3b: Cu-Cl12.4304(18),Cu-Cl2 2.3045(19),Cu-N52.027(5),Cu-N131.974(6),Cu-N162.023(5) A˚,N5-Cu-N16157.7(2),
N13-Cu-Cl2 133.86(16); in 4b: Cu-Cl1 2.439(3), Cu-Cl2 2.309(3), Cu-N5 2.021(8), Cu-N13 1.988(9), Cu-N16 2.019(8) A˚, N5-Cu-N16 158.5(4),
N13-Cu-Cl2 134.2(2).
Figure 3. ORTEP plots of metal-free ligand molecule HL5b and its
copper(II) complex in 5 3 0.5CH3OH. Selected bond distances (A˚) and
bond angles (deg) inHL5b: C4a-N5 1.417(3), N5-C6 1.359(3), C6-N13
1.329(3), N13-N14 1.382(3), N14-C15 1.297(3); in 5b: Cu-Cl1
2.4681(5), Cu-Cl2 2.2461(5), Cu-N5 2.0220(15), Cu-N14 1.9787(15),
Cu-N17 2.0466(15), N5-Cu-N14 78.94(6), N14-Cu-N17 78.18(6),
N5-Cu-N17 156.85(6), N14-Cu-Cl2 153.96(5), N14-Cu-Cl1
98.79(4).
(44) Addison, A. W.; Rao, T. N.; Reedijk, J.; van Rijn, J.; Verschoor,
G. C. J. Chem. Soc., Dalton Trans. 1984, 1349–1356.
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[N13-H 0.880, H 3 3 3Cl1
ii 2.383, N13 3 3 3Cl1
ii 3.149 A˚,
N13-H 3 3 3Cl1
ii 145.67] is evident in the crystal structure
as well.
In the complexHL5b acts as a neutral tridentate ligand
coordinating to copper(II) through the azepine ring nitro-
gen atomN5 [Cu-N5=2.022(15) A˚], hydrazine nitrogen
atom N14 [Cu-N14 = 1.9787(15) A˚], and pyridine
nitrogen atom N17 [Cu-N17 = 2.0466(15) A˚]. The
copper(II) atom is five-coordinate, the remaining binding
sites being occupied by two chlorido ligands [Cu-Cl1=
2.4681(5) A˚; Cu-Cl2=2.2461(5) A˚]. The τ descriptor for
five-coordinate complexes, expressed as the difference
between the angles N5-Cu-N17, 156.85(6), and Cl2-
Cu-N14, 153.96(5), divided by 60, gives a value of 0.05,
which is very close to the ideal one for a square pyramid
(0).44 A similar value (0.10) was reported for a closely
related complex [Cu(HL6a)Cl2].
18 It is noteworthy that
the interatomic bond distances Cu-N5 and Cu-N17 in
5b are significantly shorter than in [Cu(HL6a)Cl2],
18
whereas both Cu-Cl bonds in 5b are longer.
The conformation of the coordinated ligandHL5b in 5b
differs slightly from that adopted by the metal-free ligand
(Figure 3). The angle of 74.34(4) between themean plane
of the indole moiety and the pyridine ring in 5 is very close
to that reported for [Cu(HL6a)Cl2] (78.6).18 The bond
distances N5-C6 = 1.359(3), C6-N13 = 1.329(3) and
N13-N14 = 1.382(3) A˚ in HL5b are altered by the co-
ordination to copper(II). Whereas the N5-C6 andN13-
N14 bonds are shorter in 5b [1.298(2) A˚ and 1.358(2) A˚,
correspondingly], the bond C6-N13 = 1.362(2) A˚ is
longer, indicating the configurational change from an
exocyclic C6dN13 double bond in HL5b to an endocyclic
N5dC6 double bond in complex 5b.
Stability Studies. The kinetic stability of complexes 1a,
1b, 4a, 4b, and 5b in aqueous solution with a dimethyl-
sulfoxide content of 1% v/v was studied by UV-vis
spectroscopy over 24 h. Coordination of the correspond-
ing ligands to copper(II) via the pyridine nitrogen atom,
the hydrazine nitrogen, and the pyridine ring or azepine
ring nitrogen atom alters significantly the conjugated
π systems of the yellow-colored ligands HL1a, HL1b,
HL4a,HL4b, andHL5b, resulting in significantly different
electronic absorption spectra. As a result, solutions of
1a, 1b, 4a, 4b, and 5b show significant absorption in
the visible region, namely, a broad charge-transfer band
with a maximum at 461, 453, 461, 456, and 422 nm,
respectively (Supporting Information, Figures S7-S9). A
small decrease in absorption (ca. 5%) was observed for
1a, 1b, and 5b over the first 4 h, with no further changes
over the next 20 h, indicating that the coordination
sphere of copper(II) remained intact. These results are in
accord with those reported previously for complexes
[Cu(HL6a)Cl2] and [Cu(HL
6b)Cl2].
18 For complexes 4a
and 4b the decrease in absorption over the first 4 h is
slightly higher (ca. 7%), with no further changes over the
next 20 h.
Cytotoxicity in Cancer Cells. The cytotoxicity of the
copper(II) complexes was determined by means of a
colorimetric microculture assay (MTT) in three human
cancer cell lines (A549, CH1, SW480), yielding IC50
values in the 10-8 to 10-6 M range (Table 2). Note that
the IC50 values for cisplatin, carboplatin, and oxaliplatin
in SW480 cells are at 4.5 ( 1.7, 61 ( 10, and 0.30 (
0.08 μM.45 A549, a generally more chemoresistant cell
line, is the least sensitive to all the tested compounds,
whereas IC50 values in CH1 and SW480 cells are up to ten
and seven times lower, respectively. The corresponding
uncomplexed ligands could not be tested because of
insufficient solubility in biocompatible media.
Comparison of the copper(II) complexes reveals the
following structure-activity relationships: methyl (2a),
chloro (3a), or bromo (4a) substitution at position 8 has
nearly no impact on cytotoxicity compared to 1a lacking a
substituent in this position. In contrast, a methyl group in
position 14 results in a dramatic enhancement of cyto-
toxicity, with about 10 times lower IC50 values in A549
and CH1 and about 50 times lower IC50 values in SW480
cells in the case of compound 1b (Figure 4A-C).
Likewise, IC50 values of 2b, 3b, and 4b are 1 order of
magnitude lower than those of the analogues 2a, 3a, and
4a, confirming the impact of this methyl substitution as
well as the irrelevance of electron-releasing or electron-
withdrawing substituents at position 8.
For comparison, complexes with paullone ligands (5b,
6a, 6b) closely related to the indoloquinoline complexes
1b, 4a, and 4b, but containing a folded seven-membered
azepine ring instead of a flat six-membered pyridine ring
were also tested. In contrast to a previously reported
comparison of indoloquinoline versus paullone com-
plexes of ruthenium(II) and osmium(II) that yielded dif-
ferences of mostly 1 order of magnitude,19 differences in
cytotoxicity are much less pronounced for the copper(II)
complexes reported here. Only in SW480 cells, compar-
ison of 4b with 6b and 1b with 5b (all bearing a methyl
group in position 14 (1b, 4b) or 15 (5b, 6b)) reveals 6 and 9
times higher cytotoxicity of the indoloquinoline complex,
respectively (Figure 4D-F), whereas 4a and 6a (lacking
a substituent in position 14 and 15, correspondingly)
are comparably cytotoxic in all three cell lines. A possi-
ble reason can be the increased reactivity of the azo-
methine carbon atom C14 in 4a and the conversion of
this complex into other species, similar to [Cu(L8)2Cl2],
which may behave similar to 6a. The reason for the
Table 2.Cytotoxicity of Copper(II) Complexes with Indoloquinoline- (1a-4b) or
Paullone-Based (5b, 6a, 6b) Ligands in Three Human Cancer Cell Lines
IC50 (μM), 96 h
a
compound A549 SW480 CH1
1a 1.72 ( 0.03 1.3 ( 0.1 0.40 ( 0.07
1b 0.18 ( 0.04 0.024 ( 0.001 0.030 ( 0.005
2a 1.7 ( 0.1 0.75 ( 0.04 0.33 ( 0.07
2b 0.14 ( 0.01 0.024 ( 0.002 0.026 ( 0.006
3a 1.4 ( 0.3 0.64 ( 0.11 0.41 ( 0.05
3b 0.23 ( 0.01 0.049 ( 0.003 0.065 ( 0.012
4a 1.6 ( 0.1 0.47 ( 0.03 0.36 ( 0.03
4b 0.20 ( 0.03 0.032 ( 0.004 0.052 ( 0.008
5b 0.67 ( 0.15 0.21 ( 0.04 0.064 ( 0.015
6a 1.28 ( 0.03 0.40 ( 0.04 0.28 ( 0.03
6b 0.43 ( 0.03 0.18 ( 0.02 0.080 ( 0.005
a 50% inhibitory concentrations (means( standarddeviation fromat
least three independent experiments), as obtained by the MTT assay
using exposure times of 96 h.
(45) Mendoza-Ferri, M.-G.; Hartinger, C. G.; Eichinger, R. E.; Stolyarova,
N.; Severin, K.; Jakupec, M. A.; Nazarov, A. A.; Keppler, B. K. Organo-
metallics 2008, 27, 2405–2407.
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generally smaller differences as well as the generally
higher cytotoxicity of the copper(II) complexes may
either be related to the different central metal or to the
different metal-binding sites in the ligands and the con-
sequences of coordination to the metal or a combination
of both. Comparisons with the uncomplexed ligands were
not possible for lack of solubility, but even if the role of
the metal for biological activity remains yet unclear, it
should be emphasized that metal complexation renders
these compounds applicable for biological testing in
solution.
Final Remarks
The reported results establish synthetic access to a new
class of highly cytotoxic copper(II) complexes. Complexation
of copper(II) chloride with potentially tridentate indolo
[3,2-c]quinolines and indolo[3,2-d]benzazepines modified at
the lactam function resulted in five-coordinate copper(II)
complexes, which practically remain intact in aqueous solu-
tion containing 1% DMSO over 24 h. The complexes show
remarkably high antiproliferative activities in human cancer
cell lineswith IC50 values in the 10
-8 to 10-6Mconcentration
range. The effect of copper(II) on cytotoxicity could not be
elucidated because of the very low solubility of the metal-
free ligands in biocompatible media. Binding to copper(II)
improved the solubility of the resulted complexes, enabling
them to be tested as potential antitumor agents. The use
of 2-acetylpyridine instead of 2-formylpyridine for the
synthesis of tridentate indoloquinoline Schiff-bases results in
a huge enhancement of cytotoxicity by a factor of 10 to 50.
The presence of an electron-releasing group (methyl), or
electron-withdrawing substituents (Cl, Br) compared to H
in position 8 of the indoloquinoline backbone does not have
any effect on cytotoxicity of the corresponding copper(II)
complexes. The effect of substitution of the seven-membered
azepine ring in copper(II) complexes withmodified paullones
by a flat six-membered pyridine ring is clearly seen upon
comparing the antiproliferative activities of complexes5b and
6b with those of compounds 1b and 4b, correspondingly,
in SW480 cells, revealing a six- to nine-fold decrease of
Figure 4. Concentration-effect curves of complexes 1a, 1b, 2a, and 2b in the human cancer cell lines A549 (A), CH1 (B), SW480 (C), indicating the
different impact of methyl substitution depending on the position; and concentration-effect curves of complexes 1b and 4b in comparison with the
corresponding paullone ligands5b and 6b in the human cancer cell linesA549 (D), CH1 (E), SW480 (F), all determined by theMTTassay using continuous
exposure for 96 h.
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IC50 values. Further experiments are in progress to shed light
onto the mechanism of action of these compounds, including
their DNA-intercalating and DNA-breaking potencies. The
ability of copper(II) complexes to cut DNA is well-documen-
ted in the literature.46-50
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